BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-2191. [PMID: 15169807 DOI: 10.1200/jco.2004.11.022] [Cited by in Crossref: 1448] [Cited by in F6Publishing: 437] [Article Influence: 80.4] [Reference Citation Analysis]
Number Citing Articles
1 Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 2011;29:4436-41. [PMID: 21969504 DOI: 10.1200/JCO.2011.35.6923] [Cited by in Crossref: 55] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
2 Otaka Y, Rokudai S, Kaira K, Fujieda M, Horikoshi I, Iwakawa-Kawabata R, Yoshiyama S, Yokobori T, Ohtaki Y, Shimizu K, Oyama T, Tamura J, Prives C, Nishiyama M. STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma. Clin Cancer Res 2017;23:3442-52. [PMID: 28087642 DOI: 10.1158/1078-0432.CCR-16-1815] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
3 Qin S, Yi M, Jiao D, Li A, Wu K. Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma. J Cancer 2020;11:153-67. [PMID: 31892982 DOI: 10.7150/jca.34693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
4 Bonanno L, Favaretto A, Rugge M, Taron M, Rosell R. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs 2011;71:2231-46. [PMID: 22085382 DOI: 10.2165/11597700-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
5 Chen JH, Yang JL, Chou CY, Wang JY, Hung CC. Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer. Sci Rep 2018;8:9686. [PMID: 29946182 DOI: 10.1038/s41598-018-27994-x] [Reference Citation Analysis]
6 Sonpavde G, Bellmunt J, Schutz F, Choueiri TK. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep. 2012;14:295-306. [PMID: 22532265 DOI: 10.1007/s11912-012-0237-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
7 Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012;2:a006577. [PMID: 23028128 DOI: 10.1101/cshperspect.a006577] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 13.2] [Reference Citation Analysis]
8 Chan A. Antiangiogenic therapy for metastatic breast cancer: current status and future directions. Drugs 2009;69:167-81. [PMID: 19228074 DOI: 10.2165/00003495-200969020-00003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
9 Trukhin D, Poddubskaya E, Andric Z, Makharadze T, Bellala RS, Charoentum C, Yañez Ruiz EP, Fulop A, Hyder Ali IA, Syrigos K, Katgi N, Lopez Chuken YA, Rumyana I, Reyes-Igama J, Costamilan RC, Del Campo García A, Florez A, Paravisini A, Millan S; STELLA Investigators. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA). BioDrugs 2021;35:429-44. [PMID: 33914256 DOI: 10.1007/s40259-021-00483-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Raig ET, Jones NB, Varker KA, Benniger K, Go MR, Biber JL, Lesinski GB, Carson WE 3rd. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res 2008;28:553-61. [PMID: 18771339 DOI: 10.1089/jir.2008.0118] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
11 Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Coan A, Threatt S, Friedman AH, Friedman HS. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011;117:5351-8. [PMID: 21590689 DOI: 10.1002/cncr.26188] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
12 Duignan IJ, Corcoran E, Pennello A, Plym MJ, Amatulli M, Claros N, Iacolina M, Youssoufian H, Witte L, Samakoglu S, Schwartz J, Surguladze D, Tonra JR. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models. Neoplasia 2011;13:49-59. [PMID: 21245940 DOI: 10.1593/neo.101162] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
13 Reinmuth N, Bryl M, Bondarenko I, Syrigos K, Vladimirov V, Zereu M, Bair AH, Hilton F, Liau K, Kasahara K. PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. BioDrugs 2019;33:555-70. [PMID: 31338773 DOI: 10.1007/s40259-019-00363-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
14 Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J Cancer 2020;11:4474-94. [PMID: 32489466 DOI: 10.7150/jca.44313] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
15 Yuan M, Zhai Y, Men Y, Wang J, Deng L, Wang W, Bao Y, Yang X, Sun S, Ma Z, Liu Y, Wang J, Zhu H, Hui Z. Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis. Thorac Cancer 2021;12:3208-15. [PMID: 34676669 DOI: 10.1111/1759-7714.14188] [Reference Citation Analysis]
16 Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. Front Oncol 2014;4:157. [PMID: 25019058 DOI: 10.3389/fonc.2014.00157] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
17 Mortimer J, Zonder HB, Pal SK. Lessons learned from the bevacizumab experience. Cancer Control 2012;19:309-16. [PMID: 23037498 DOI: 10.1177/107327481201900407] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
18 Takagi Y, Toriihara A, Nakahara Y, Yomota M, Okuma Y, Hosomi Y, Shibuya M, Okamura T. Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study. PLoS One 2013;8:e59700. [PMID: 23555751 DOI: 10.1371/journal.pone.0059700] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
19 Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285. [PMID: 21252716 DOI: 10.1097/jto.0b013e318206a221] [Cited by in Crossref: 2694] [Cited by in F6Publishing: 1213] [Article Influence: 244.9] [Reference Citation Analysis]
20 Ahuja J, Shroff GS, Strange CD, Vlahos I, Benveniste MFK, Truong MT. Pearls and Pitfalls in the Imaging of Targeted Therapy and Immunotherapy in Lung Cancer. Semin Ultrasound CT MR 2021;42:552-62. [PMID: 34895611 DOI: 10.1053/j.sult.2021.04.015] [Reference Citation Analysis]
21 Yu Z, Cai X, Xu Z, He Z, Lai J, Wang W, Zhang J, Kong W, Huang X, Chen Y, Shi Y, Shi X, Zhao Z, Ni M, Lin X, Chen S, Wu X, Chen W, Song Z, Huang C. Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial. Oncologist 2020;25:e1640-9. [PMID: 32533785 DOI: 10.1634/theoncologist.2020-0519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chen J, Lu Y, Zheng Y. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2015;9:4751-60. [PMID: 26316712 DOI: 10.2147/DDDT.S87258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
23 Kadota K, Nitadori J, Rekhtman N, Jones DR, Adusumilli PS, Travis WD. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis. Am J Surg Pathol 2015;39:1170-80. [PMID: 25871623 DOI: 10.1097/PAS.0000000000000439] [Cited by in Crossref: 45] [Cited by in F6Publishing: 15] [Article Influence: 6.4] [Reference Citation Analysis]
24 Ferreira M, Secher T, Heuze-Vourc'H N, Reckamp KL. Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. Pharmaceutics 2021;13:912. [PMID: 34205484 DOI: 10.3390/pharmaceutics13060912] [Reference Citation Analysis]
25 Tsai MH, Hsiao YP, Lin WL, Tseng SW. Steatocystoma multiplex as initial impression of non-small cell lung cancer with complete response to gefitinib. Chin J Cancer Res 2014;26:E5-9. [PMID: 24653640 DOI: 10.3978/j.issn.1000-9604.2014.01.02] [Reference Citation Analysis]
26 Chen ZI, Ai DI. Cardiotoxicity associated with targeted cancer therapies. Mol Clin Oncol 2016;4:675-81. [PMID: 27123262 DOI: 10.3892/mco.2016.800] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
27 Carbajo-Pescador S, Ordoñez R, Benet M, Jover R, García-Palomo A, Mauriz JL, González-Gallego J. Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 2013;109:83-91. [PMID: 23756865 DOI: 10.1038/bjc.2013.285] [Cited by in Crossref: 140] [Cited by in F6Publishing: 136] [Article Influence: 15.6] [Reference Citation Analysis]
28 Zhou CC, Bai CX, Guan ZZ, Jiang GL, Shi YK, Wang MZ, Wu YL, Zhang YP, Zhu YZ. Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. Clin Transl Oncol 2014;16:463-8. [PMID: 24002945 DOI: 10.1007/s12094-013-1102-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
29 Hida K, Maishi N, Annan DA, Hida Y. Contribution of Tumor Endothelial Cells in Cancer Progression. Int J Mol Sci. 2018;19. [PMID: 29695087 DOI: 10.3390/ijms19051272] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 22.8] [Reference Citation Analysis]
30 Rapp J, Jaromi L, Kvell K, Miskei G, Pongracz JE. WNT signaling - lung cancer is no exception. Respir Res 2017;18:167. [PMID: 28870231 DOI: 10.1186/s12931-017-0650-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 8.6] [Reference Citation Analysis]
31 Gadgeel SM, Cote ML, Schwartz AG, Matherly LH, Wozniak A, Bepler G. Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resist Updat 2010;13:196-204. [PMID: 21051275 DOI: 10.1016/j.drup.2010.10.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
32 Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 2019;24:731-70. [PMID: 31049758 DOI: 10.1007/s10147-019-01431-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
33 Zhao Y, Wang R, Shen X, Pan Y, Cheng C, Li Y, Shen L, Zhang Y, Li H, Zheng D, Ye T, Zheng S, Sun Y, Chen H. Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis. Ann Surg Oncol 2016;23:2099-105. [PMID: 26842488 DOI: 10.1245/s10434-015-5043-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 7.2] [Reference Citation Analysis]
34 Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14:277-284. [PMID: 22532266 DOI: 10.1007/s11912-012-0238-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
35 Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-12. [PMID: 19224857 DOI: 10.1200/JCO.2008.16.2412] [Cited by in Crossref: 108] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
36 Navani N, Brown JM, Nankivell M, Woolhouse I, Harrison RN, Jeebun V, Munavvar M, Ng BJ, Rassl DM, Falzon M, Kocjan G, Rintoul RC, Nicholson AG, Janes SM. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med 2012;185:1316-22. [PMID: 22505743 DOI: 10.1164/rccm.201202-0294OC] [Cited by in Crossref: 149] [Cited by in F6Publishing: 77] [Article Influence: 14.9] [Reference Citation Analysis]
37 Gerdes MJ, Sood A, Sevinsky C, Pris AD, Zavodszky MI, Ginty F. Emerging understanding of multiscale tumor heterogeneity. Front Oncol. 2014;4:366. [PMID: 25566504 DOI: 10.3389/fonc.2014.00366] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
38 Rossi A, Maione P, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D, Palazzolo G, Falanga M, Colantuoni G, Gridelli C. New angiogenic agents and non-small cell lung cancer: current results and future development. Targ Oncol 2007;2:211-23. [DOI: 10.1007/s11523-007-0060-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 2014;7:70. [PMID: 25277503 DOI: 10.1186/s13045-014-0070-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 10.5] [Reference Citation Analysis]
40 Chirieac LR, Dacic S. Targeted Therapies in Lung Cancer. Surg Pathol Clin 2010;3:71-82. [PMID: 20680095 DOI: 10.1016/j.path.2010.04.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
41 McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-12. [PMID: 19078952 DOI: 10.1038/sj.bjc.6604808] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 6.9] [Reference Citation Analysis]
42 Isla D, González-Rojas N, Nieves D, Brosa M, Finnern HW. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol 2011;13:460-71. [PMID: 21775273 DOI: 10.1007/s12094-011-0683-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
43 Clément-Duchêne C, Godbert B, Martinet Y. [Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities]. Rev Mal Respir 2012;29:161-77. [PMID: 22405111 DOI: 10.1016/j.rmr.2011.06.017] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, Jakopović M, Brčić L, Knežević J. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. J Pers Med 2021;11:1102. [PMID: 34834454 DOI: 10.3390/jpm11111102] [Reference Citation Analysis]
45 Micke P, Botling J, Mattsson JSM, Planck M, Tran L, Vidarsdottir H, Nodin B, Jirström K, Brunnström H. Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer. Sci Rep 2019;9:1319. [PMID: 30718697 DOI: 10.1038/s41598-018-37722-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
46 Stathopoulos GP, Dimitroulis J, Antoniou D, Katis C, Tsavdaridis D, Armenaki O, Marosis C, Michalopoulou P, Grigoratou T, Stathopoulos J. Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial. Br J Cancer 2005;93:1106-11. [PMID: 16251879 DOI: 10.1038/sj.bjc.6602827] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
47 Tanaka F, Yoneda K. Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). Surg Today 2016;46:25-37. [PMID: 25925615 DOI: 10.1007/s00595-015-1174-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
48 Lai XX, Xu RA, Yu-Ping L, Yang H. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 2016;9:2421-8. [PMID: 27143937 DOI: 10.2147/OTT.S96156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
49 Kzhyshkowska J, Larionova I, Liu T. YKL-39 as a Potential New Target for Anti-Angiogenic Therapy in Cancer. Front Immunol 2019;10:2930. [PMID: 32038607 DOI: 10.3389/fimmu.2019.02930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
50 Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist 2011;16:486-96. [PMID: 21441299 DOI: 10.1634/theoncologist.2010-0287] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
51 Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7:e35629. [PMID: 22539986 DOI: 10.1371/journal.pone.0035629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
52 Giannelli G, Azzariti A, Fransvea E, Porcelli L, Antonaci S, Paradiso A. Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells. Br J Cancer 2004;91:1964-9. [PMID: 15545972 DOI: 10.1038/sj.bjc.6602231] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
53 Dawe DE, Ellis PM. Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System. J Pers Med 2012;2:77-92. [PMID: 25562202 DOI: 10.3390/jpm2030077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
54 Chaft JE, Sima CS, Ginsberg MS, Huang J, Kris MG, Travis WD, Azzoli CG. Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung. J Thorac Oncol 2012;7:1400-5. [PMID: 22895138 DOI: 10.1097/JTO.0b013e3182614856] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
55 Cedrych I, Kruczała MA, Walasek T, Jakubowicz J, Blecharz P, Reinfuss M. Systemic treatment of non-small cell lung cancer brain metastases. Contemp Oncol (Pozn) 2016;20:352-7. [PMID: 28373815 DOI: 10.5114/wo.2016.64593] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
56 Imran M, Akhileshwar Jha L, Hasan N, Shrestha J, Pangeni R, Parvez N, Mohammed Y, Kumar Jha S, Raj Paudel K. “Nanodecoys”- Future of drug delivery by encapsulating nanoparticles in natural cell membranes. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.121790] [Reference Citation Analysis]
57 Tolnay E, Ghimessy ÁK, Juhász E, Sztancsik Z, Losonczy G, Dombi P, Vennes Z, Helf L, Csada E, Sárosi V. The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study. Oncol Lett 2019;17:1750-60. [PMID: 30675234 DOI: 10.3892/ol.2018.9766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 Pang RW, Poon RT. Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag. 2006;2:97-108. [PMID: 17319453 DOI: 10.2147/vhrm.2006.2.2.97] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
59 Kim YN, Lee HY, Lee KS, Seo JB, Chung MJ, Ahn MJ, Park K, Kim TS, Yi CA. Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response? Korean J Radiol 2012;13:702-10. [PMID: 23118568 DOI: 10.3348/kjr.2012.13.6.702] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
60 Jun N, Hanping W, Xiaoyan S, Yan X, Mengzhao W, Xiaotong Z, Li Z. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. Thorac Cancer 2020;11:1869-75. [PMID: 32406994 DOI: 10.1111/1759-7714.13469] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Torii C, Maishi N, Kawamoto T, Morimoto M, Akiyama K, Yoshioka Y, Minami T, Tsumita T, Alam MT, Ochiya T, Hida Y, Hida K. miRNA-1246 in extracellular vesicles secreted from metastatic tumor induces drug resistance in tumor endothelial cells. Sci Rep 2021;11:13502. [PMID: 34226586 DOI: 10.1038/s41598-021-92879-5] [Reference Citation Analysis]
62 Gerber DE, Swanson P, Lopez-Chavez A, Wong L, Dowlati A, Pennell NA, Cronier DM, Qin A, Ilaria R Jr, Cosaert J, Shahir A, Baggstrom MQ. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. Lung Cancer 2017;111:108-15. [PMID: 28838379 DOI: 10.1016/j.lungcan.2017.07.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
63 Zhuang J, Yu Y, Li Z, Lu S. Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis. Oncotarget 2017;8:53675-83. [PMID: 28881841 DOI: 10.18632/oncotarget.15726] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
64 Heymach JV. ZD6474--clinical experience to date. Br J Cancer 2005;92 Suppl 1:S14-20. [PMID: 15928653 DOI: 10.1038/sj.bjc.6602604] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
65 Burris H, Stephenson J, Otterson GA, Stein M, McGreivy J, Sun YN, Ingram M, Ye Y, Schwartzberg LS. Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. J Oncol 2011;2011:853931. [PMID: 21559248 DOI: 10.1155/2011/853931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Prat A, Casado E, Cortés J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007; 13(44): 5857-5866 [PMID: 17990351 DOI: 10.3748/wjg.v13.i44.5857] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
67 Hida K, Ohga N, Hida Y, Shindoh M. Significance of anti-angiogenic therapy in head and neck cancer—Heterogeneity of tumor endothelium. Japanese Dental Science Review 2010;46:26-32. [DOI: 10.1016/j.jdsr.2009.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
68 Sun L, Ma JT, Zhang SL, Zou HW, Han CB. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. Med Oncol 2015;32:473. [PMID: 25603953 DOI: 10.1007/s12032-014-0473-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
69 Ueki A, Okuma T, Hamamoto S, Kageyama K, Murai K, Miki Y. Combination therapy involving radiofrequency ablation and targeted chemotherapy with bevacizumab plus paclitaxel and cisplatin in a rabbit VX2 lung tumor model. BMC Res Notes 2018;11:251. [PMID: 29690935 DOI: 10.1186/s13104-018-3358-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
70 Yahata M, Nakaya I, Sakuma T, Sato H, Aoki S, Soma J. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature. BMC Res Notes 2013;6:450. [PMID: 24207130 DOI: 10.1186/1756-0500-6-450] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
71 Hida K, Ohga N, Akiyama K, Maishi N, Hida Y. Heterogeneity of tumor endothelial cells. Cancer Sci 2013;104:1391-5. [PMID: 23930621 DOI: 10.1111/cas.12251] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
72 Bukowski RM. Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. Cancer Manag Res 2010;2:83-96. [PMID: 21188099 DOI: 10.2147/cmar.s7540] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
73 Chandra S, Chandra H, Sindhwani G. Role of rapid on-site evaluation with cyto-histopathological correlation in diagnosis of lung lesion. J Cytol 2014;31:189-93. [PMID: 25745282 DOI: 10.4103/0970-9371.151128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
74 Haseltine JM, Rimner A, Gelblum DY, Modh A, Rosenzweig KE, Jackson A, Yorke ED, Wu AJ. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol 2016;6:e27-33. [PMID: 26577006 DOI: 10.1016/j.prro.2015.09.012] [Cited by in Crossref: 77] [Cited by in F6Publishing: 83] [Article Influence: 11.0] [Reference Citation Analysis]
75 Fujii M, Kobayakawa M, Saito K, Inano A, Morita A, Hasegawa M, Mukasa A, Mitsuhara T, Goto T, Yamaguchi S, Tamiya T, Nakatomi H, Oya S, Takahashi F, Sato T, Bakhit M, On Behalf Of The BeatNF Trial Investigators. Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma. Curr Oncol 2021;28:726-39. [PMID: 33572546 DOI: 10.3390/curroncol28010071] [Reference Citation Analysis]
76 Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015;12:511-26. [PMID: 25963091 DOI: 10.1038/nrclinonc.2015.90] [Cited by in Crossref: 155] [Cited by in F6Publishing: 157] [Article Influence: 22.1] [Reference Citation Analysis]
77 Yimaer W, Abudouyimu A, Tian Y, Magaoweiya S, Bagedati D, Wen H. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 2016;9:1167-73. [PMID: 27022276 DOI: 10.2147/OTT.S102265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
78 de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007;9:412-23. [PMID: 17622648 DOI: 10.1215/15228517-2007-024] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 7.5] [Reference Citation Analysis]
79 Yamakawa M, Doh SJ, Santosa SM, Montana M, Qin EC, Kong H, Han KY, Yu C, Rosenblatt MI, Kazlauskas A, Chang JH, Azar DT. Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review. Med Res Rev 2018;38:1769-98. [PMID: 29528507 DOI: 10.1002/med.21496] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
80 Hirsh V. Review of the treatment of metastatic non small cell lung carcinoma: A practical approach. World J Clin Oncol 2011; 2(6): 262-271 [PMID: 21773076 DOI: 10.5306/wjco.v2.i6.262] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
81 Herbst RS. Introduction. Seminars in Oncology 2005;32:1-2. [DOI: 10.1053/j.seminoncol.2005.10.003] [Reference Citation Analysis]
82 Righi L, Franzi F, Montarolo F, Gatti G, Bongiovanni M, Sessa F, La Rosa S. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)-from morphology to molecular testing. J Thorac Dis 2017;9:S395-404. [PMID: 28603651 DOI: 10.21037/jtd.2017.03.158] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
83 Tsironis G, Ziogas DC, Kyriazoglou A, Lykka M, Koutsoukos K, Bamias A, Dimopoulos MA. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore? Ann Transl Med. 2018;6:143. [PMID: 29862232 DOI: 10.21037/atm.2018.02.18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
84 Abou Faycal C, Brambilla E, Agorreta J, Lepeltier N, Jacquet T, Lemaître N, Emadali A, Lucas A, Lacal PM, Montuenga L, Pio R, Gazzeri S, Eymin B. The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma. Br J Cancer 2018;118:1596-608. [PMID: 29795310 DOI: 10.1038/s41416-018-0128-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
85 West H. The evolving role of targeted therapy in early-stage and locally advanced non-small cell lung cancer. Curr Oncol Rep 2011;13:280-9. [PMID: 21633785 DOI: 10.1007/s11912-011-0181-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
86 Yu KH, Wang F, Berry GJ, Ré C, Altman RB, Snyder M, Kohane IS. Classifying non-small cell lung cancer types and transcriptomic subtypes using convolutional neural networks. J Am Med Inform Assoc 2020;27:757-69. [PMID: 32364237 DOI: 10.1093/jamia/ocz230] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
87 Villaruz LC, Socinski MA. The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep 2015;17:26. [PMID: 25947099 DOI: 10.1007/s11912-015-0448-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
88 Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol 2010;12:985-90. [PMID: 20363768 DOI: 10.1093/neuonc/noq033] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
89 Kyle F, Spicer J. Targeted therapies in non-small cell lung cancer. Cancer Imaging 2008;8:199-205. [PMID: 19028612 DOI: 10.1102/1470-7330.2008.0027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
90 Gurda GT, Zhang L, Wang Y, Chen L, Geddes S, Cho WC, Askin F, Gabrielson E, Li QK. Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases. Clin Transl Med 2015;4:16. [PMID: 25977750 DOI: 10.1186/s40169-015-0057-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
91 Graham DM, Leighl NB. Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. Front Oncol 2014;4:258. [PMID: 25295228 DOI: 10.3389/fonc.2014.00258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
92 Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18. [DOI: 10.1038/nrclinonc.2009.110] [Cited by in Crossref: 257] [Cited by in F6Publishing: 224] [Article Influence: 19.8] [Reference Citation Analysis]
93 Duhig EE, Clarke BE. Updating the 2011 International Association for the Study of Lung Cancer classification of lung adenocarcinoma: main priorities and implications for clinicians. Lung Cancer Management 2014;3:149-58. [DOI: 10.2217/lmt.14.4] [Reference Citation Analysis]
94 Goto K, Endo M, Kusumoto M, Yamamoto N, Ohe Y, Shimizu A, Fukuoka M. Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis. Cancer Sci 2016;107:1837-42. [PMID: 27714941 DOI: 10.1111/cas.13096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
95 Singh N, Mootha VK, Madan K, Aggarwal AN, Behera D. Tumor cavitation among lung cancer patients receiving first-line chemotherapy at a tertiary care centre in India: association with histology and overall survival. Med Oncol 2013;30:602. [PMID: 23673987 DOI: 10.1007/s12032-013-0602-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
96 Zhang C, Yang H, Lang B, Yu X, Xiao P, Zhang D, Fan L, Zhang X. Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma. Cancer Manag Res 2018;10:2401-7. [PMID: 30122989 DOI: 10.2147/CMAR.S165660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
97 Jin Y, Wei L, Jiang Q, Song X, Teng C, Fan C, Lv Y, Liu Y, Shen W, Li L, Huang D, Xin T. Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model. Sci Rep 2018;8:15837. [PMID: 30367145 DOI: 10.1038/s41598-018-34030-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
98 Vincent MD. Promising targets and current clinical trials in metastatic squamous cell lung cancer. Front Oncol 2014;4:320. [PMID: 25538887 DOI: 10.3389/fonc.2014.00320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
99 Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget 2014;5:10280-92. [PMID: 25373733 DOI: 10.18632/oncotarget.2163] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
100 Lunacsek OE, Ravelo A, Coutinho AD, Hazard SJ, Green MR, Willey J, Eaddy M, Goertz HP. First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices. Drugs Real World Outcomes 2016;3:333-43. [PMID: 27747837 DOI: 10.1007/s40801-016-0090-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
101 Ozaki Y, Yoshimura A, Sawaki M, Hattori M, Gondo N, Kotani H, Adachi Y, Kataoka A, Sugino K, Horisawa N, Endo Y, Nozawa K, Sakamoto S, Iwata H. Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report. World J Clin Oncol 2020; 11(7): 504-509 [PMID: 32821655 DOI: 10.5306/wjco.v11.i7.504] [Reference Citation Analysis]
102 Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:264-270. [PMID: 19047285 DOI: 10.1200/jco.2008.17.4656] [Cited by in Crossref: 40] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
103 Peng Y, Chen Y, Zhang X, Yang Y, Cao D, Bi F, Li Z, Gou H. Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy. J Cancer Res Clin Oncol 2018;144:1339-46. [PMID: 29774414 DOI: 10.1007/s00432-018-2656-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
104 Liu C, Alwarappan S, Badr HA, Zhang R, Liu H, Zhu JJ, Li CZ. Live cell integrated surface plasmon resonance biosensing approach to mimic the regulation of angiogenic switch upon anti-cancer drug exposure. Anal Chem 2014;86:7305-10. [PMID: 25005895 DOI: 10.1021/ac402659j] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
105 Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-8. [PMID: 17982442 DOI: 10.1038/nature06358] [Cited by in Crossref: 780] [Cited by in F6Publishing: 733] [Article Influence: 52.0] [Reference Citation Analysis]
106 Osarogiagbon RU. Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. J Thorac Dis 2012;4:214-6. [PMID: 22833830 DOI: 10.3978/j.issn.2072-1439.2012.03.06] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
107 Shimizu K, Maeda A, Yukawa T, Nojima Y, Saisho S, Okita R, Nakata M. Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma. World J Surg Oncol 2014;12:343. [PMID: 25392182 DOI: 10.1186/1477-7819-12-343] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
108 Infante JR, Arkenau HT, Bendell JC, Rubin MS, Waterhouse D, Jones GT, Spigel DR, Lane CM, Hainsworth JD, Burris HA 3rd. Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial. Cancer Biol Ther 2013;14:340-6. [PMID: 23358470 DOI: 10.4161/cbt.23625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
109 Stinchcombe TE. Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. Med Oncol 2014;31:960. [PMID: 24748366 DOI: 10.1007/s12032-014-0960-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
110 Corrales L, Nogueira A, Passiglia F, Listi A, Caglevic C, Giallombardo M, Raez L, Santos E, Rolfo C. Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. Front Med (Lausanne) 2017;4:13. [PMID: 28293555 DOI: 10.3389/fmed.2017.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
111 Bhattacharya A. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opin Drug Deliv 2011;8:749-63. [PMID: 21473705 DOI: 10.1517/17425247.2011.571672] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
112 Brouzas D, Koutsandrea C, Moschos M, Papadimitriou S, Ladas I, Apostolopoulos M. Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin) for AMD followed by controlateral sympathetic ophthalmia. Clin Ophthalmol 2009;3:457-9. [PMID: 19714263 DOI: 10.2147/opth.s4641] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
113 Rajabi M, Mousa SA. The Role of Angiogenesis in Cancer Treatment. Biomedicines 2017;5:E34. [PMID: 28635679 DOI: 10.3390/biomedicines5020034] [Cited by in Crossref: 188] [Cited by in F6Publishing: 150] [Article Influence: 37.6] [Reference Citation Analysis]
114 Wang R, Li K, Pi J, Meng L, Zhu M. Cavitation and fatal hemoptysis after immunotherapy for advanced lung adenocarcinoma: A case report. Thorac Cancer 2020;11:2727-30. [PMID: 32691523 DOI: 10.1111/1759-7714.13578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Dansin E, Lauridant G, Chahine B. [Antiangiogenic agents: current limits in thoracic oncology]. Bull Cancer 2012;99:1083-91. [PMID: 23113985 DOI: 10.1684/bdc.2012.1655] [Reference Citation Analysis]
116 Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381-1389. [PMID: 20538785 DOI: 10.1681/asn.2010020167] [Cited by in Crossref: 141] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
117 Liu ZJ, Wang J, Wei XY, Chen P, Wang LC, Lin L, Sun BC, Li K. Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer. J Cancer Res Clin Oncol 2012;138:927-37. [PMID: 22331237 DOI: 10.1007/s00432-012-1167-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
118 Kuo YH, Lin CH, Shau WY, Chen TJ, Yang SH, Huang SM, Hsu C, Lu YS, Cheng AL. Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer 2012;12:620. [PMID: 23268621 DOI: 10.1186/1471-2407-12-620] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
119 Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. Oncotarget 2017;8:42949-61. [PMID: 28487489 DOI: 10.18632/oncotarget.17306] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
120 Stroyakovskiy DL, Fadeeva NV, Matrosova MP, Shelepen KG, Adamchuk GA, Roy B, Nagarkar R, Kalloli M, Zhuravleva D, Voevodin GD, Shustova MS, Kryukov F. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. BMC Cancer 2022;22:129. [PMID: 35105329 DOI: 10.1186/s12885-022-09243-7] [Reference Citation Analysis]
121 Qian X, Qin J, Pan S, Li X, Pan Y, Ma S. Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis. PLoS One 2015;10:e0139026. [PMID: 26402447 DOI: 10.1371/journal.pone.0139026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
122 Cui J, Cai X, Zhu M, Liu T, Zhao N. The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials. PLoS One 2013;8:e62038. [PMID: 23614008 DOI: 10.1371/journal.pone.0062038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
123 Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs 2015;33:215-24. [PMID: 25363205 DOI: 10.1007/s10637-014-0176-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
124 Huang C, Wang X, Wang J, Lin L, Liu Z, Xu W, Wang L, Xiao J, Li K. Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor. Thorac Cancer 2014;5:438-46. [PMID: 26767036 DOI: 10.1111/1759-7714.12115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
125 McLean AEB, Barnes DJ, Troy LK. Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine. J Clin Med. 2018;7:163. [PMID: 29966246 DOI: 10.3390/jcm7070163] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
126 Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e195S-e226S. [PMID: 22315261 DOI: 10.1378/chest.11-2296] [Cited by in Crossref: 896] [Cited by in F6Publishing: 753] [Article Influence: 89.6] [Reference Citation Analysis]
127 Gridelli C, Maione P, Rossi A, Ferrara C, Colantuoni G, Del Gaizo F, Nicolella D, Guerriero C. Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients. Targ Oncol 2006;1:13-22. [DOI: 10.1007/s11523-005-0006-x] [Reference Citation Analysis]
128 Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010;60:222-243. [PMID: 20554717 DOI: 10.3322/caac.20075] [Cited by in Crossref: 311] [Cited by in F6Publishing: 273] [Article Influence: 25.9] [Reference Citation Analysis]
129 Hakozaki T, Okuma Y, Hashimoto K, Hosomi Y. Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis. J Cancer Res Clin Oncol 2019;145:2555-64. [PMID: 31350622 DOI: 10.1007/s00432-019-02985-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
130 Katz Y, Somer RA. Maintenance therapy for metastatic non-small-cell lung cancer - the role of pemetrexed. Lung Cancer (Auckl) 2010;1:1-7. [PMID: 28210102 DOI: 10.2147/lctt.s7105] [Reference Citation Analysis]
131 Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2011;6:e22681. [PMID: 21829644 DOI: 10.1371/journal.pone.0022681] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.1] [Reference Citation Analysis]
132 Hirsh V. New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther 2017;10:2513-26. [PMID: 28546756 DOI: 10.2147/OTT.S104177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
133 Nadjafi M, Sung MR, Santos GDC, Le LW, Hwang DM, Tsao MS, Leighl NB. Diagnostic patterns of non-small-cell lung cancer at Princess Margaret Cancer Centre. Curr Oncol 2020;27:244-9. [PMID: 33173375 DOI: 10.3747/co.27.5757] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
134 Dulak J, Józkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 2005;5:579-94. [PMID: 16375664 DOI: 10.2174/156800905774932824] [Cited by in Crossref: 120] [Cited by in F6Publishing: 116] [Article Influence: 7.5] [Reference Citation Analysis]
135 Jao K, Labbe C, Leighl NB. Ready or not? Lung cancer diagnosis in 2015. Curr Oncol 2015;22:239-42. [PMID: 26300660 DOI: 10.3747/co.22.2647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
136 Blais N, Corrales-Rodriguez L. Personalized choice of maintenance therapies in non-small-cell lung cancer. Curr Oncol 2012;19:S64-72. [PMID: 22787413 DOI: 10.3747/co.19.1068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
137 Carcereny Costa E, Viñolas Segarra N, Gascón Vilaplana P. Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Clin Transl Oncol 2008;10:198-203. [PMID: 18411192 DOI: 10.1007/s12094-008-0182-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
138 Wang H, Qin M, Liu R, Ding X, Chen ISY, Jiang Y. Characterization of A Bifunctional Synthetic RNA Aptamer and A Truncated Form for Ability to Inhibit Growth of Non-Small Cell Lung Cancer. Sci Rep 2019;9:18836. [PMID: 31827170 DOI: 10.1038/s41598-019-55280-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
139 Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A 2012;109:E353-9. [PMID: 22203991 DOI: 10.1073/pnas.1105026109] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
140 Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 2015;7:133-43. [PMID: 26082660 DOI: 10.2147/CMAR.S77400] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 6.1] [Reference Citation Analysis]
141 Liu Y, Yuan D, Ye W, Lv T, Song Y. Prognostic value of circulating endothelial cells in non-small cell lung cancer patients: a systematic review and meta-analysis. Transl Lung Cancer Res 2015;4:610-8. [PMID: 26629430 DOI: 10.3978/j.issn.2218-6751.2015.10.03] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
142 Kader YA, Le Chevalier T, El-Nahas T, Sakr A. Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. Onco Targets Ther 2013;6:803-9. [PMID: 23836994 DOI: 10.2147/OTT.S45906] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
143 Barrett CL, Schwab RB, Jung H, Crain B, Goff DJ, Jamieson CH, Thistlethwaite PA, Harismendy O, Carson DA, Frazer KA. Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancer. PLoS One 2013;8:e58714. [PMID: 23527012 DOI: 10.1371/journal.pone.0058714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
144 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
145 Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G. [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. Zhongguo Fei Ai Za Zhi 2010;13:171-89. [PMID: 20681066 DOI: 10.3779/j.issn.1009-3419.2010.03.15] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
146 Gridelli C, Rossi A, Maione P. Treatment of non-small cell lung cancer and targeted therapies: where are we? Curr Opin Oncol 2005;17:114-7. [PMID: 15725914 DOI: 10.1097/01.cco.0000152630.20996.48] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
147 Chen S, Sun J, Zhao L, Sun Y, Jia D, Song Y, Luo J, Lei H, Liu N. Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment. Exp Ther Med 2021;21:62. [PMID: 33365062 DOI: 10.3892/etm.2020.9494] [Reference Citation Analysis]
148 Dubinski W, Leighl NB, Tsao MS, Hwang DM. Ancillary testing in lung cancer diagnosis. Pulm Med 2012;2012:249082. [PMID: 22263108 DOI: 10.1155/2012/249082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
149 Yao M, Galanopoulos N, Lavertu P, Fu P, Gibson M, Argiris A, Rezaee R, Zender C, Wasman J, Machtay M, Savvides P. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck 2015;37:1665-71. [PMID: 24954745 DOI: 10.1002/hed.23813] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
150 Hasenöhrl N. [Bevacizumab in the first-line therapy of advanced NSCLC]. Wien Med Wochenschr 2007;157:576-8. [PMID: 18157597 DOI: 10.1007/s10354-007-0491-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Brown L, Wan H. Desmoglein 3: a help or a hindrance in cancer progression? Cancers (Basel) 2015;7:266-86. [PMID: 25629808 DOI: 10.3390/cancers7010266] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
152 Daaboul N, Nicholas G, Laurie SA. Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview. Curr Oncol 2018;25:S77-85. [PMID: 29910650 DOI: 10.3747/co.25.3792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
153 Farhat FS, Houhou W. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther Adv Med Oncol 2013;5:249-70. [PMID: 23858333 DOI: 10.1177/1758834013492001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
154 Kontoyiannis DP. Manipulation of host angioneogenesis: A critical link for understanding the pathogenesis of invasive mold infections? Virulence 2010;1:192-6. [PMID: 21178441 DOI: 10.4161/viru.1.3.11380] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
155 Gadgeel SM. The optimal chemotherapy for stage III non-small cell lung cancer patients. Curr Oncol Rep 2011;13:272-9. [PMID: 21479993 DOI: 10.1007/s11912-011-0170-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
156 Jagieła J, Bartnicki P, Rysz J. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. Int J Mol Sci 2021;22:4618. [PMID: 33924827 DOI: 10.3390/ijms22094618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Miao L, Guo S, Lin CM, Liu Q, Huang L. Nanoformulations for combination or cascade anticancer therapy. Adv Drug Deliv Rev 2017;115:3-22. [PMID: 28624477 DOI: 10.1016/j.addr.2017.06.003] [Cited by in Crossref: 99] [Cited by in F6Publishing: 86] [Article Influence: 19.8] [Reference Citation Analysis]
158 Li X, Shi G, Chu Q, Jiang W, Liu Y, Zhang S, Zhang Z, Wei Z, He F, Guo Z, Qi L. A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas. BMC Genomics 2019;20:881. [PMID: 31752667 DOI: 10.1186/s12864-019-6086-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
159 Singh T, Fatehi Hassanabad M, Fatehi Hassanabad A. Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. Biochim Biophys Acta Rev Cancer 2021;1876:188636. [PMID: 34655692 DOI: 10.1016/j.bbcan.2021.188636] [Reference Citation Analysis]
160 Toschi L, Rossi S, Finocchiaro G, Santoro A. Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. Ecancermedicalscience 2017;11:787. [PMID: 29225694 DOI: 10.3332/ecancer.2017.787] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
161 Newsome BW, Ernstoff MS. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol 2008;66:6-19. [PMID: 18503606 DOI: 10.1111/j.1365-2125.2008.03187.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
162 Zhang X, Kuang Y, Zhang Y, He K, Lechtzin N, Zeng M, Yung RC, Xie C. Shifted focus of bronchoalveolar lavage in patients with suspected thoracic malignancy: an analysis of 224 patients. J Thorac Dis 2016;8:3245-54. [PMID: 28066604 DOI: 10.21037/jtd.2016.11.06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
163 Salgia R. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Med 2014;3:681-92. [PMID: 24711160 DOI: 10.1002/cam4.238] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
164 Zhao X, Wang M, Zhang L, Li L, Zhong W. [Evaluation of efficacy and safety of bevacizumab combined with chemotherapy for Chinese patients with advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2012;15:6-10. [PMID: 22237117 DOI: 10.3779/j.issn.1009-3419.2012.01.02] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Baxevanos P, Mountzios G. Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau? Ann Transl Med 2018;6:139. [PMID: 29862228 DOI: 10.21037/atm.2018.04.04] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
166 Xing P, Hao X, Hu X, Wang Y, Li J. [Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma]. Zhongguo Fei Ai Za Zhi 2016;19:670-4. [PMID: 27760596 DOI: 10.3779/j.issn.1009-3419.2016.10.06] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
167 Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc Am Thorac Soc 2009;6:206-17. [PMID: 19349490 DOI: 10.1513/pats.200807-066LC] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
168 Ogita S, Wozniak AJ. Refining the treatment of advanced nonsmall cell lung cancer. Lung Cancer (Auckl) 2010;1:9-22. [PMID: 28210103 DOI: 10.2147/lctt.s6075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One 2013;8:e51780. [PMID: 23349675 DOI: 10.1371/journal.pone.0051780] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
170 Liu Y, Tian P. [Progress of Bevacizumab in Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2019;22:118-24. [PMID: 30827329 DOI: 10.3779/j.issn.1009-3419.2019.02.07] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
171 Ataídes FG, Silva SFBR, Baldin JJCMC. Radiation-Induced Optic Neuropathy: Literature Review. Neuroophthalmology 2021;45:172-80. [PMID: 34194124 DOI: 10.1080/01658107.2020.1817946] [Reference Citation Analysis]
172 Ericson Lindquist K, Gudinaviciene I, Mylona N, Urdar R, Lianou M, Darai-Ramqvist E, Haglund F, Béndek M, Bardoczi E, Dobra K, Brunnström H. Real-World Diagnostic Accuracy and Use of Immunohistochemical Markers in Lung Cancer Diagnostics. Biomolecules 2021;11:1721. [PMID: 34827719 DOI: 10.3390/biom11111721] [Reference Citation Analysis]
173 Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol 2017;28:2932-42. [PMID: 28950290 DOI: 10.1093/annonc/mdx514] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 13.5] [Reference Citation Analysis]
174 Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 2010;30:229-41. [PMID: 20225906 DOI: 10.2165/11532260-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
175 Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 2014;9:e89960. [PMID: 24599121 DOI: 10.1371/journal.pone.0089960] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
176 Seto R, Yamada H, Wada H, Osawa M, Nagao T, Nakano Y. Diffuse alveolar haemorrhage may be associated with intravitreal injection of bevacizumab in a patient with systemic risk factors. BMJ Case Rep 2011;2011:bcr0820103224. [PMID: 22714606 DOI: 10.1136/bcr.08.2010.3224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
177 Daum S, Hagen H, Naismith E, Wolf D, Pircher A. The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition. Front Cell Dev Biol 2020;8:610903. [PMID: 33469537 DOI: 10.3389/fcell.2020.610903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
178 Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66. [PMID: 19917871 DOI: 10.1200/JCO.2009.23.5622] [Cited by in Crossref: 549] [Cited by in F6Publishing: 199] [Article Influence: 42.2] [Reference Citation Analysis]
179 Villaruz LC, Socinski MA. Personalized therapy for non-small cell lung cancer: which drug for which patient? Semin Thorac Cardiovasc Surg 2011;23:281-90. [PMID: 22443647 DOI: 10.1053/j.semtcvs.2012.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
180 Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther 2009;8:2263-72. [PMID: 19829059 DOI: 10.4161/cbt.8.23.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
181 Zhang Y, Xie F, Mao X, Zheng X, Li Y, Zhu L, Sun J. Determining factors of endobronchial ultrasound-guided transbronchial needle aspiration specimens for lung cancer subtyping and molecular testing. Endosc Ultrasound. 2019;8:404-411. [PMID: 31670289 DOI: 10.4103/eus.eus_8_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
182 Shen C, Kehl KL, Zhao B, Simon GR, Zhou S, Giordano SH. Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer. Clin Lung Cancer 2017;18:e233-41. [PMID: 28024927 DOI: 10.1016/j.cllc.2016.11.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
183 Bondarenko IM, Ingrosso A, Bycott P, Kim S, Cebotaru CL. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer. BMC Cancer 2015;15:339. [PMID: 25929582 DOI: 10.1186/s12885-015-1350-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
184 Schettino C, Bareschino MA, Rossi A, Maione P, Castaldo V, Mazzeo N, Sacco PC, Ferrara ML, Palazzolo G, Ciardiello F, Gridelli C. The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. Ther Adv Med Oncol 2009;1:5-13. [PMID: 21789109 DOI: 10.1177/1758834009338635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
185 Gerber DE, Putnam WC, Fattah FJ, Kernstine KH, Brekken RA, Pedrosa I, Skelton R, Saltarski JM, Lenkinski RE, Leff RD, Ahn C, Padmanabhan C, Chembukar V, Kasiri S, Kallem RR, Subramaniyan I, Yuan Q, Do QN, Xi Y, Reznik SI, Pelosof L, Faubert B, DeBerardinis RJ, Kim J. Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer. Clin Cancer Res 2020;26:6017-27. [PMID: 32847935 DOI: 10.1158/1078-0432.CCR-20-1916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
186 Vo KT, Matthay KK, DuBois SG. Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clin Sarcoma Res 2016;6:9. [PMID: 27274393 DOI: 10.1186/s13569-016-0049-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
187 Triano LR, Deshpande H, Gettinger SN. Management of patients with advanced non-small cell lung cancer: current and emerging options. Drugs 2010;70:167-79. [PMID: 20108990 DOI: 10.2165/11532200-000000000-00000] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
188 Clark T, Jo SJ, Phillips A. Sample Size for Biosimilar Trials: In Defense of Synthesis. Ther Innov Regul Sci 2018;52:300-5. [PMID: 29714537 DOI: 10.1177/2168479017729189] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
189 Rajabi M, Mousa SA. The Role of Angiogenesis in Cancer Treatment. Biomedicines 2017;5:E34. [PMID: 28635679 DOI: 10.3390/biomedicines5020034] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
190 Wozniak AJ, Moon J, Thomas CR Jr, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 2015;16:340-7. [PMID: 25703100 DOI: 10.1016/j.cllc.2014.12.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
191 Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Cuello M, Corrales L, Martín C, Ortiz C, Franco S, Rosell R; CLICaP. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. PLoS One 2016;11:e0154293. [PMID: 27191954 DOI: 10.1371/journal.pone.0154293] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
192 Payne LS, Huang PH. Discoidin domain receptor 2 signaling networks and therapy in lung cancer. J Thorac Oncol 2014;9:900-4. [PMID: 24828669 DOI: 10.1097/JTO.0000000000000164] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
193 Greillier L, Tomasini P, Barlesi F. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience. Ther Adv Respir Dis 2016;10:485-91. [PMID: 27340254 DOI: 10.1177/1753465816652083] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
194 Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman BB 3rd, Stewart CF. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res 2014;20:2783-92. [PMID: 24637635 DOI: 10.1158/1078-0432.CCR-13-2364] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
195 Gold KA, Kim ES, Wistuba II, Hong WK. Personalizing lung cancer prevention through a reverse migration strategy. Top Curr Chem 2013;329:221-40. [PMID: 22752582 DOI: 10.1007/128_2012_338] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
196 Zhou M, Yu P, Qu X, Liu Y, Zhang J. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis. PLoS One 2013;8:e81858. [PMID: 24324725 DOI: 10.1371/journal.pone.0081858] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
197 Patil PD, Shapiro M, Hashemi Sadraei N, Pennell NA. An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer. Oncologist 2019;24:457-e126. [PMID: 30602615 DOI: 10.1634/theoncologist.2018-0857] [Reference Citation Analysis]
198 Oka S, Shinohara S, Kuwata T, Takenaka M, Chikaishi Y, Hirai A, Ichiki Y, Shimajiri S, Aoki T, Tanaka F. The major thoracic vascular invasion of lung cancer. Ann Med Surg (Lond) 2017;20:13-8. [PMID: 28702181 DOI: 10.1016/j.amsu.2017.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
199 Nishino M, Hatabu H, Sholl LM, Ramaiya NH. Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. Radiographics 2017;37:1371-87. [PMID: 28898185 DOI: 10.1148/rg.2017170015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
200 Marín-Pozo JF, Duarte-Pérez JM, Sánchez-Rovira P. Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience. Medicine (Baltimore) 2016;95:e3623. [PMID: 27175672 DOI: 10.1097/MD.0000000000003623] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
201 Piperdi B, Merla A, Perez-Soler R. Targeting angiogenesis in squamous non-small cell lung cancer. Drugs 2014;74:403-13. [PMID: 24578213 DOI: 10.1007/s40265-014-0182-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
202 Larrayoz M, Pio R, Pajares MJ, Zudaire I, Ajona D, Casanovas O, Montuenga LM, Agorreta J. Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype. EMBO Mol Med 2014;6:539-50. [PMID: 24500694 DOI: 10.1002/emmm.201303214] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
203 Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 2017;8:51492-51506. [PMID: 28881662 DOI: 10.18632/oncotarget.18190] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
204 Blumenschein GR Jr. Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). Invest New Drugs 2012;30:1802-11. [PMID: 21987350 DOI: 10.1007/s10637-011-9750-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
205 Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 15.1] [Reference Citation Analysis]
206 Pietanza MC, Hellmann MD, Fiore JJ, Smith-Marrone S, Basch EM, Schwartz LH, Ginsberg MS, Shouery M, Newman SK, Shaw M, Rogak LJ, Lash AE, Hilden P, Kris MG. Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. J Thorac Oncol 2016;11:890-9. [PMID: 26964771 DOI: 10.1016/j.jtho.2016.02.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
207 Stantz KM, Cao M, Cao N, Liang Y, Miller KD. Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT. Mol Imaging Biol 2011;13:1183-95. [PMID: 20957443 DOI: 10.1007/s11307-010-0441-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
208 Liu Y, Li HM, Wang R. Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. Front Med (Lausanne) 2021;8:616380. [PMID: 34277647 DOI: 10.3389/fmed.2021.616380] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:6006-11. [PMID: 19826110 DOI: 10.1200/JCO.2009.23.7545] [Cited by in Crossref: 94] [Cited by in F6Publishing: 50] [Article Influence: 7.2] [Reference Citation Analysis]
210 Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012;17:715-24. [PMID: 22531357 DOI: 10.1634/theoncologist.2012-0024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
211 Souza FF, Smith A, Araujo C, Jagannathan J, Johnston C, O'Regan K, Shinagare A, Ramaiya N. New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know. Cancer Imaging 2014;14:26. [PMID: 25608887 DOI: 10.1186/1470-7330-14-26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
212 Zhang YC, Zhou Q, Wu YL. Emerging challenges of advanced squamous cell lung cancer. ESMO Open 2016;1:e000129. [PMID: 28255454 DOI: 10.1136/esmoopen-2016-000129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
213 Chitikela S, Pathak N, Malik PS. Under the Magnifying Glass: Searching for The Evidence of Pemetrexed in Nonsquamous Nonsmall Cell Lung Cancer. Indian J Med Paediatr Oncol 2021;42:579-81. [DOI: 10.1055/s-0041-1735516] [Reference Citation Analysis]
214 Gadgeel SM. New targets in non-small cell lung cancer. Curr Oncol Rep 2013;15:411-23. [PMID: 23771519 DOI: 10.1007/s11912-013-0326-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
215 Lu Z, Wientjes TS, Au JL. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors. Pharm Res 2005;22:1069-78. [PMID: 16028007 DOI: 10.1007/s11095-005-6038-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
216 Lu ZJ, Song QF, Jiang SS, Song Q, Wang W, Zhang GH, Kan B, Chen LJ, Yang JL, Luo F, Qian ZY, Wei YQ, Gou LT. Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen. BMC Cancer 2009;9:16. [PMID: 19144153 DOI: 10.1186/1471-2407-9-16] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
217 Hoeppner LH, Wang Y, Sharma A, Javeed N, Van Keulen VP, Wang E, Yang P, Roden AC, Peikert T, Molina JR, Mukhopadhyay D. Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. Mol Oncol 2015;9:270-81. [PMID: 25226814 DOI: 10.1016/j.molonc.2014.08.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
218 Vaziri SA, Kim J, Ganapathi MK, Ganapathi R. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep 2010;12:102-8. [PMID: 20425594 DOI: 10.1007/s11912-010-0085-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
219 Cho BC, Kim JH, Soo RA, Yang CH. The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer. Yonsei Med J 2010;51:1-8. [PMID: 20046507 DOI: 10.3349/ymj.2010.51.1.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
220 de Sá VK, Carvalho L, Gomes A, Alarcão A, Silva MR, Couceiro P, Sousa V, Soares FA, Capelozzi VL. Role of the extracellular matrix in variations of invasive pathways in lung cancers. Braz J Med Biol Res 2013;46:21-31. [PMID: 23314337 DOI: 10.1590/1414-431x20122263] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
221 Friedman JR, Richbart SD, Merritt JC, Brown KC, Nolan NA, Akers AT, Lau JK, Robateau ZR, Miles SL, Dasgupta P. Acetylcholine signaling system in progression of lung cancers. Pharmacol Ther 2019;194:222-54. [PMID: 30291908 DOI: 10.1016/j.pharmthera.2018.10.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
222 Pories SE, Wulf GM. Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. Breast Cancer (Dove Med Press) 2010;2:37-44. [PMID: 24367165 DOI: 10.2147/bctt.s6511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
223 Wang Y, Yan P, Liu Z, Yang X, Wang Y, Shen Z, Bai H, Wang J, Wang Z. MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation. Thorac Cancer 2016;7:279-87. [PMID: 27148412 DOI: 10.1111/1759-7714.12325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
224 Bareschino MA, Schettino C, Rossi A, Maione P, Sacco PC, Zeppa R, Gridelli C. Treatment of advanced non small cell lung cancer. J Thorac Dis 2011;3:122-33. [PMID: 22263075 DOI: 10.3978/j.issn.2072-1439.2010.12.08] [Cited by in F6Publishing: 43] [Reference Citation Analysis]
225 Bhatti V, Kwatra KS, Puri S, Calton N. Histopathological Spectrum and Immunohistochemical Profile of Lung Carcinomas: A 9-Year Study from a Tertiary Hospital in North India. Int J Appl Basic Med Res 2019;9:169-75. [PMID: 31392181 DOI: 10.4103/ijabmr.IJABMR_66_19] [Reference Citation Analysis]
226 Visconti R, Morra F, Guggino G, Celetti A. The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. Int J Mol Sci 2017;18:E1374. [PMID: 28653990 DOI: 10.3390/ijms18071374] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
227 Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R, Yang JC, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer 2018;125:273-81. [PMID: 30429032 DOI: 10.1016/j.lungcan.2018.08.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
228 Hornberger J, Degtiar I, Gutierrez H, Shewade A, Henner WD, Becker S, Varadhachary G, Raab S. Cost-effectiveness of gene-expression profiling for tumor-site origin. Value Health 2013;16:46-56. [PMID: 23337215 DOI: 10.1016/j.jval.2012.09.005] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
229 Ulahannan SV, Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 2011;29:325-37. [PMID: 21469981 DOI: 10.3109/07357907.2011.554476] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 4.6] [Reference Citation Analysis]
230 Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007;67:2045-75. [PMID: 17883287 DOI: 10.2165/00003495-200767140-00006] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 6.2] [Reference Citation Analysis]
231 Aftab BT, Dobromilskaya I, Liu JO, Rudin CM. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res 2011;71:6764-72. [PMID: 21896639 DOI: 10.1158/0008-5472.CAN-11-0691] [Cited by in Crossref: 93] [Cited by in F6Publishing: 48] [Article Influence: 8.5] [Reference Citation Analysis]
232 Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res 2019;38:156. [PMID: 30975211 DOI: 10.1186/s13046-019-1094-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 19.3] [Reference Citation Analysis]
233 Santos ES, Gomez JE, Raez LE. Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Invest New Drugs 2012;30:1261-9. [PMID: 21350804 DOI: 10.1007/s10637-011-9644-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
234 Zhang D, Zhang C, Huang J, Guan Y, Guo Q. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study. Thorac Cancer 2018;9:1754-62. [PMID: 30338916 DOI: 10.1111/1759-7714.12898] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
235 Leighl NB. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol 2012;19:S52-8. [PMID: 22787411 DOI: 10.3747/co.19.1114] [Cited by in Crossref: 58] [Cited by in F6Publishing: 73] [Article Influence: 5.8] [Reference Citation Analysis]
236 Sheng J, Yang YP, Yang BJ, Zhao YY, Ma YX, Hong SD, Zhang YX, Zhao HY, Huang Y, Zhang L. Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review. Medicine (Baltimore) 2015;94:e1282. [PMID: 26252298 DOI: 10.1097/MD.0000000000001282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
237 Staudacher L, Teixeira L, Kempf E, Rousseau-Bussac G, Jouveshomme S, Cohen R, Beuzelin C, Jagot JL, Salmeron S, Trédaniel J. [Targeted agents in the treatment of lung cancer]. Pathol Biol (Paris) 2012;60:246-53. [PMID: 22743094 DOI: 10.1016/j.patbio.2012.05.011] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
238 Castañeda-Gill JM, Vishwanatha JK. Antiangiogenic mechanisms and factors in breast cancer treatment. J Carcinog 2016;15:1. [PMID: 27013929 DOI: 10.4103/1477-3163.176223] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
239 Goss GD, Spaans JN. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung. Oncologist 2016;21:205-13. [PMID: 26768483 DOI: 10.1634/theoncologist.2015-0209] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
240 Ito M, Niho S, Nihei K, Yoh K, Ohmatsu H, Ohe Y. Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer 2012;12:27. [PMID: 22260460 DOI: 10.1186/1471-2407-12-27] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
241 Hall RD, Le TM, Haggstrom DE, Gentzler RD. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2015;4:515-23. [PMID: 26629420 DOI: 10.3978/j.issn.2218-6751.2015.06.09] [Cited by in F6Publishing: 44] [Reference Citation Analysis]
242 Wan R, Dong X, Chen Q, Yu Y, Yang S, Zhang X, Zhang G, Pan Y, Sun S, Zhou C, Hong W, Zhao H, Yang L, Huang L, Wu R, Zang A, Ma R, Wu L, Lv D, Fu X, Han J, Li W, Duan J, Wang K, Jiang O, Chen Y, Guo Z, Gao H, Wen J, Wang S, Zhao E, Li G, Yue L, Liang L, Zeng A, Wang X, Zhu Y, Pan H, Dai Z, Feng W, Zhao G, Lin C, Li C, Li N, Bao Y, Li Y, Su Y, Zhao M, Fang H, Zhu Y, Zhang Y, Ding L, Wang Y, Yuan X, Wang J. Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study. EClinicalMedicine 2021;42:101187. [PMID: 34841235 DOI: 10.1016/j.eclinm.2021.101187] [Reference Citation Analysis]
243 Rekhtman N, Tafe LJ, Chaft JE, Wang L, Arcila ME, Colanta A, Moreira AL, Zakowski MF, Travis WD, Sima CS, Kris MG, Ladanyi M. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol 2013;26:511-22. [PMID: 23196793 DOI: 10.1038/modpathol.2012.195] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 7.3] [Reference Citation Analysis]
244 Des Guetz G. [Biotherapy in colorectal cancer]. J Chir (Paris) 2005;142:291-6. [PMID: 16292207 DOI: 10.1016/s0021-7697(05)80932-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
245 Tabchi S, Blais N. Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine. Front Oncol 2017;7:52. [PMID: 28424759 DOI: 10.3389/fonc.2017.00052] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
246 Mazières J, Dansin E. [Efficacy and tolerance of bevacizumab in non-small cell lung cancer: preliminary report]. Rev Pneumol Clin 2008;64:166-72. [PMID: 19019283 DOI: 10.1016/j.pneumo.2008.07.004] [Reference Citation Analysis]
247 De Castro J, González-Larriba JL, Vázquez S, Massutí B, Sanchez-Torres JM, Dómine M, Garrido P, Calles A, Artal A, Collado R, García R, Sereno M, Majem M, Macías JA, Juan O, Gómez-Codina J, Hernández B, Lázaro M, Ortega AL, Cobo M, Trigo JM, Carcereny E, Rolfo C, Macia S, Muñoz J, Diz P, Méndez M, Rosillo F, Paz-Ares L, Cardona JV, Isla D. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. Clin Transl Oncol 2017;19:219-26. [PMID: 27371031 DOI: 10.1007/s12094-016-1527-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
248 Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer. 2011;104:413-418. [PMID: 21245868 DOI: 10.1038/sj.bjc.6606074] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
249 Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs 2015;33:700-9. [PMID: 25902899 DOI: 10.1007/s10637-015-0238-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
250 Cohen MH, Johnson JR, Chattopadhyay S, Tang S, Justice R, Sridhara R, Pazdur R. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist 2010;15:1344-51. [PMID: 21148614 DOI: 10.1634/theoncologist.2010-0257] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
251 Bria E, Bonomi M, Pilotto S, Massari F, Novello S, Levra MG, Tortora G, Scagliotti G. Clinical meta-analyses of targeted therapies in adenocarcinoma. Target Oncol 2013;8:35-45. [PMID: 23354875 DOI: 10.1007/s11523-013-0262-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
252 Zhu X, Tian X, Yu C, Hong J, Fang J, Chen H. Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials. Medicine (Baltimore) 2016;95:e4232. [PMID: 27559943 DOI: 10.1097/MD.0000000000004232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
253 Boolell V, Alamgeer M, Watkins DN, Ganju V. The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) 2015;7:1815-46. [PMID: 26371045 DOI: 10.3390/cancers7030864] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 9.6] [Reference Citation Analysis]
254 Korpanty G, Smyth E, Sullivan LA, Brekken RA, Carney DN. Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med (Maywood) 2010;235:3-9. [PMID: 20404013 DOI: 10.1258/ebm.2009.009191] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
255 Kurkjian C, Kim ES. Risks and benefits with bevacizumab: evidence and clinical implications. Ther Adv Drug Saf 2012;3:59-69. [PMID: 25083226 DOI: 10.1177/2042098611430109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
256 Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007;8:15-27. [PMID: 17634832 DOI: 10.1007/s11864-007-0022-4] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 6.0] [Reference Citation Analysis]
257 Nie F, Xu HX, Tang Q, Lu MD. Microbubble-enhanced ultrasound exposure improves gene transfer in vascular endothelial cells. World J Gastroenterol 2006; 12(46): 7508-7513 [PMID: 17167842 DOI: 10.3748/wjg.v12.i46.7508] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
258 Marrinucci D, Bethel K, Luttgen M, Bruce RH, Nieva J, Kuhn P. Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. Arch Pathol Lab Med 2009;133:1468-71. [PMID: 19722757 DOI: 10.5858/133.9.1468] [Cited by in Crossref: 7] [Cited by in F6Publishing: 39] [Article Influence: 0.5] [Reference Citation Analysis]
259 Han S, Hong Y, Liu T, Wu N, Ye Z. The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Oncotarget 2018;9:14619-29. [PMID: 29581868 DOI: 10.18632/oncotarget.23657] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
260 Glade Bender J, Blaney SM, Borinstein S, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report. Clin Cancer Res 2012;18:5081-9. [PMID: 22791883 DOI: 10.1158/1078-0432.CCR-12-0078] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
261 Snider KL, Maitland ML. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol 2009;4:67-76. [PMID: 19373440 DOI: 10.1007/s11523-009-0106-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
262 Gao Y, Song F, Zhang P, Liu J, Cui J, Ma Y, Zhang G, Luo J. Improving the Subtype Classification of Non-small Cell Lung Cancer by Elastic Deformation Based Machine Learning. J Digit Imaging 2021;34:605-17. [PMID: 33963422 DOI: 10.1007/s10278-021-00455-0] [Reference Citation Analysis]
263 Zhu Y, Xing P, Li J. [Treatment of Advanced Squamous Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2016;19:687-91. [PMID: 27760600 DOI: 10.3779/j.issn.1009-3419.2016.10.10] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
264 Négrier S, Pérol D, Bahleda R, Hollebecque A, Chatelut E, Boyle H, Cassier P, Metzger S, Blanc E, Soria JC, Escudier B. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. BMC Cancer 2017;17:547. [PMID: 28810837 DOI: 10.1186/s12885-017-3527-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
265 Tang Z, Wang Y, Yu Y, Cui Y, Liang L, Xu C, Shen Z, Shen K, Wang X, Liu T, Sun Y. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. BMC Med 2022;20:107. [PMID: 35382819 DOI: 10.1186/s12916-022-02309-0] [Reference Citation Analysis]
266 Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs 2015;33:177-86. [PMID: 25323060 DOI: 10.1007/s10637-014-0173-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
267 Revannasiddaiah S, Thakur P, Bhardwaj B, Susheela SP, Madabhavi I. Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. J Thorac Dis 2014;6:S502-25. [PMID: 25349702 DOI: 10.3978/j.issn.2072-1439.2014.05.19] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
268 Lammers PE, Horn L. Targeting angiogenesis in advanced non-small cell lung cancer. J Natl Compr Canc Netw 2013;11:1235-47. [PMID: 24142825 DOI: 10.6004/jnccn.2013.0146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
269 Wang CL, Gao LT, Lyu CX, Zhang Q, Zeng WQ, Fang WT, Zhu L, Fu XL. Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors. Med Oncol 2022;39:25. [PMID: 34982283 DOI: 10.1007/s12032-021-01620-9] [Reference Citation Analysis]
270 Furrukh M, Al-Moundhri M, Zahid KF, Kumar S, Burney I. Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC). Sultan Qaboos Univ Med J 2013;13:202-17. [PMID: 23862025 DOI: 10.12816/0003225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
271 Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, Yu HJ, Nalcioglu O, Su MY. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol. 2009;16:1619-1628. [PMID: 19333654 DOI: 10.1245/s10434-009-0441-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
272 Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol 2013;2:49-65. [PMID: 23750318 DOI: 10.2217/cns.12.36] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 11.4] [Reference Citation Analysis]
273 Ivanyi P, Winkler T, Ganser A, Reuter C, Grünwald V. Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. Dtsch Arztebl Int 2008;105:232-7. [PMID: 19629201 DOI: 10.3238/arztebl.2008.0232] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
274 Furrukh M, Burney IA, Kumar S, Zahid KF, Al-Moundhri M. Improving Outcomes in Advanced Lung Cancer: Maintenance therapy in non-small-cell lung carcinoma. Sultan Qaboos Univ Med J 2013;13:3-18. [PMID: 23573377 DOI: 10.12816/0003190] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
275 Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006;14:505-515. [PMID: 16601950 DOI: 10.1007/s00520-006-0055-4] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 5.4] [Reference Citation Analysis]
276 Zhang T, Yuan S, Wang Z, Zhang Q, Zhao P, Shan L. [Bevacizumab combined with chemotherapy for advanced non-small cell lung cancer: a meta-analysis]. Zhongguo Fei Ai Za Zhi 2013;16:82-90. [PMID: 23425900 DOI: 10.3779/j.issn.1009-3419.2013.02.05] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
277 DeLozier AM, Brown J, Natanegara F, Zhao L, Cui ZL, Able SL, Bowman L, Treat J, Hess LM. Study protocol: systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer. Syst Rev 2014;3:102. [PMID: 25227571 DOI: 10.1186/2046-4053-3-102] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
278 Yamagishi T, Shimizu K, Ochi N, Yamane H, Irei I, Sadahira Y, Takigawa N, Oka M, Nakata M. Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma. Diagn Pathol 2014;9:103. [PMID: 24885169 DOI: 10.1186/1746-1596-9-103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
279 Bearz A, Berretta M, Lleshi A, Tirelli U. Target therapies in lung cancer. J Biomed Biotechnol. 2011;2011:921231. [PMID: 21541198 DOI: 10.1155/2011/921231] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
280 Cheng G, Zhang L. [Adverse events related to bevacizumab and the management principles in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2010;13:563-7. [PMID: 20681440 DOI: 10.3779/j.issn.1009-3419.2010.06.001] [Reference Citation Analysis]
281 Ghimessy AK, Gellert A, Schlegl E, Hegedus B, Raso E, Barbai T, Timar J, Ostoros G, Megyesfalvi Z, Gieszer B, Moldvay J, Renyi-Vamos F, Lohinai Z, Hoda MA, Klikovits T, Klepetko W, Laszlo V, Dome B. KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy. Cancers (Basel) 2019;11:E1514. [PMID: 31600989 DOI: 10.3390/cancers11101514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
282 Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007;58:95-103. [PMID: 17610986 DOI: 10.1016/j.lungcan.2007.05.017] [Cited by in Crossref: 122] [Cited by in F6Publishing: 118] [Article Influence: 8.1] [Reference Citation Analysis]
283 Li T. Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes? J Thorac Dis 2010;2:189-91. [PMID: 22263043 DOI: 10.3978/j.issn.2072-1439.2010.11.9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
284 Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther 2011;4:43-58. [PMID: 21691577 DOI: 10.2147/OTT.S18155] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
285 Koh YW, Park CS, Yoon DH, Suh C, Huh J. CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma. PLoS One 2014;9:e87066. [PMID: 24489836 DOI: 10.1371/journal.pone.0087066] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
286 Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther 2013;6:1393-8. [PMID: 24124381 DOI: 10.2147/OTT.S51164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
287 Blumenthal DT, Mendel L, Bokstein F. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter? J Neurooncol 2016;127:493-502. [PMID: 26721244 DOI: 10.1007/s11060-015-2025-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
288 Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 2010;15:130-41. [PMID: 20139170 DOI: 10.1634/theoncologist.2009-0252] [Cited by in Crossref: 81] [Cited by in F6Publishing: 59] [Article Influence: 6.8] [Reference Citation Analysis]
289 Zhou Y, Hu XW, Yang SJ, Yu Z. Knockdown of LncRNAZFAS1 suppresses cell proliferation and metastasis in non-small cell lung cancer. Anim Cells Syst (Seoul) 2020;24:107-13. [PMID: 32489690 DOI: 10.1080/19768354.2020.1736623] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
290 Reck M, Mellemgaard A. Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib. Biologics 2015;9:47-56. [PMID: 26170616 DOI: 10.2147/BTT.S57356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
291 Li J, Zhao Z, Wu X, Yao J, Ma L, Ye R, Niu B, Liang L, Zhao X, Wang Q. Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinoma. Onco Targets Ther 2015;8:1315-9. [PMID: 26082647 DOI: 10.2147/OTT.S80159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
292 Feng L, Wang Z, Jing L, Zhou Z, Shi S, Deng R, Liu Y, Meng Q. Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis. World J Surg Oncol 2021;19:64. [PMID: 33637113 DOI: 10.1186/s12957-021-02161-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
293 Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, Vici P, Bianco V, Tomao F. Bevacizumab in ovarian cancer: A critical review of phase III studies. Oncotarget 2017;8:12389-405. [PMID: 27852039 DOI: 10.18632/oncotarget.13310] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
294 Yang D, Dai R, Zhang Q, Fang P. Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review. Saudi J Biol Sci 2018;25:888-94. [PMID: 30108437 DOI: 10.1016/j.sjbs.2017.12.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
295 Hu B, Zhou X, Liu Y, Li Q, Xiang M, Zou B, Peng F, Huang M, Gong Y, Zhu J, Wang Y, Ren L, Xu Y, Zhang Y, Li Y, Yu M, Xue J, Deng L, Wang J, Ding Z, Lu Y. Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. Oncol Lett 2018;15:5671-9. [PMID: 29556304 DOI: 10.3892/ol.2018.8064] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
296 Wang S, Liu Y, Feng Y, Zhang J, Swinnen J, Li Y, Ni Y. A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. Cancers (Basel) 2019;11:E1782. [PMID: 31766180 DOI: 10.3390/cancers11111782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
297 Hu Y, Tian M, Zhang H. Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer. J Biomed Biotechnol 2012;2012:419402. [PMID: 22529706 DOI: 10.1155/2012/419402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
298 Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther. 2013;13:745-758. [PMID: 23773106 DOI: 10.1586/era.13.47] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 7.3] [Reference Citation Analysis]
299 Hellmann MD, Chaft JE, Rusch V, Ginsberg MS, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA, Paik PK. Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. Cancer Chemother Pharmacol 2013;72:453-61. [PMID: 23811982 DOI: 10.1007/s00280-013-2219-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
300 Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 2015;26:1427-33. [PMID: 25908603 DOI: 10.1093/annonc/mdv197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
301 Reck M, Gatzemeier U. Advanced non-small cell lung cancer therapy: historical and future perspectives. Targ Oncol 2008;3:135-47. [DOI: 10.1007/s11523-008-0082-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
302 Moreland A, Novogrodsky E, Brody L, Durack J, Erinjeri J, Getrajdman G, Solomon S, Yarmohammadi H, Maybody M. Pneumothorax with prolonged chest tube requirement after CT-guided percutaneous lung biopsy: incidence and risk factors. Eur Radiol 2016;26:3483-91. [PMID: 26787605 DOI: 10.1007/s00330-015-4200-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
303 Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol 2008;19:1903-9. [PMID: 18632723 DOI: 10.1093/annonc/mdn412] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
304 Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer 2016;122:766-72. [PMID: 26695526 DOI: 10.1002/cncr.29812] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 6.7] [Reference Citation Analysis]
305 Stinchcombe TE. Current management of RET rearranged non-small cell lung cancer. Ther Adv Med Oncol 2020;12:1758835920928634. [PMID: 32782485 DOI: 10.1177/1758835920928634] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
306 Quinton C, Ellis PM. An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC). Cancers (Basel) 2011;3:3506-24. [PMID: 24212966 DOI: 10.3390/cancers3033506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
307 Hong S, Tan M, Wang S, Luo S, Chen Y, Zhang L. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2015;141:909-21. [PMID: 25373315 DOI: 10.1007/s00432-014-1862-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
308 Boolell V, Alamgeer M, Watkins DN, Ganju V. The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) 2015;7:1815-46. [PMID: 26371045 DOI: 10.3390/cancers7030864] [Reference Citation Analysis]
309 Saavedra E, Hollebecque A, Soria JC, Hartl DM. Dysphonia induced by anti-angiogenic compounds. Invest New Drugs 2014;32:774-82. [PMID: 24343672 DOI: 10.1007/s10637-013-0049-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
310 Ustuner Z, Meltem Akay O, Keskin M, Kuş E, Bal C, Gulbas Z. Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography. Med Oncol 2012;29:3125-8. [DOI: 10.1007/s12032-012-0274-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
311 Nagane M, Nishikawa R, Narita Y, Kobayashi H, Takano S, Shinoura N, Aoki T, Sugiyama K, Kuratsu J, Muragaki Y, Sawamura Y, Matsutani M. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 2012;42:887-95. [PMID: 22844129 DOI: 10.1093/jjco/hys121] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
312 Gridelli C, Camerini A, Pappagallo G, Pennella A, Anzidei M, Bellomi M, Buosi R, Grasso RF. Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC). Cancer Imaging 2016;16:44. [PMID: 28031049 DOI: 10.1186/s40644-016-0102-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
313 Halpenny D, O'Dwyer E, Girshman J, Ginsberg MS. Imaging of Novel Oncologic Treatments in Lung Cancer Part 1: Systemic Therapies. J Thorac Imaging 2020;35:26-36. [PMID: 31855947 DOI: 10.1097/RTI.0000000000000451] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
314 Veena VS, Saritha VN, George PS, Rajan K, Jayasree K, Sujathan K. Immunoexpression of TTF1 and p63 Differentiates Lung Adenocarcinomas in Sputum Samples. J Cytol 2021;38:151-7. [PMID: 34703092 DOI: 10.4103/JOC.JOC_252_16] [Reference Citation Analysis]
315 Lind JS, Smit EF. Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Ther Adv Med Oncol 2009;1:95-107. [PMID: 21789115 DOI: 10.1177/1758834009338633] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
316 Alshangiti A, Chandhoke G, Ellis PM. Antiangiogenic therapies in non-small-cell lung cancer. Curr Oncol 2018;25:S45-58. [PMID: 29910647 DOI: 10.3747/co.25.3747] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
317 Walraven M, Homs MYV, van der Veldt AAM, Dekker H, Koldenhof J, Honeywell R, Barendrecht A, Sebastian SAE, Parr N, Koekman AC, Voest EE, Roest M, Korporaal SJA, Verheul HMW. Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab. Angiogenesis 2018;21:325-34. [PMID: 29532289 DOI: 10.1007/s10456-018-9598-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
318 Senoo S, Ninomiya K, Hotta K, Kiura K. Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. Int J Clin Oncol 2019;24:461-7. [PMID: 30847617 DOI: 10.1007/s10147-019-01424-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
319 Najjar F, Alammar M, Bachour M, Almalla N, Altahan M, Alali A, Al-Massarani G. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy. J Cancer Res Clin Oncol 2015;141:119-25. [PMID: 25037116 DOI: 10.1007/s00432-014-1778-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
320 Mandrekar SJ, Sargent DJ. Randomized phase II trials: time for a new era in clinical trial design. J Thorac Oncol 2010;5:932-4. [PMID: 20581575 DOI: 10.1097/JTO.0b013e3181e2eadf] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
321 Salvador C, Li B, Hansen R, Cramer DE, Kong M, Yan J. Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res 2008;14:1239-47. [PMID: 18281559 DOI: 10.1158/1078-0432.CCR-07-1669] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
322 Hayashi H, Kurata T, Nakagawa K. Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer. Clin Med Insights Oncol 2011;5:177-84. [PMID: 21695043 DOI: 10.4137/CMO.S6252] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
323 Masago K, Fujimoto D, Fujita S, Hata A, Kaji R, Ohtsuka K, Okuda C, Takeshita J, Katakami N. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer. Mol Clin Oncol 2015;3:415-9. [PMID: 25798278 DOI: 10.3892/mco.2014.457] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
324 Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Ozaka M, Ogura M, Chin K, Yamaguchi T. Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. Onco Targets Ther 2015;8:243-9. [PMID: 25670906 DOI: 10.2147/OTT.S75722] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
325 Hess LM, DeLozier AM, Natanegara F, Wang X, Soldatenkova V, Brnabic A, Able SL, Brown J. First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis. J Thorac Dis 2018;10:6677-94. [PMID: 30746213 DOI: 10.21037/jtd.2018.11.87] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
326 Vergnenègre A, Basse V, Le Garff G, Bylicki O, Dubos-Arvis C, Comet B, Marcq M, Le Treut J, Auliac JB, Madroszyk A, Fraboulet G, Crequit J, Thomas P, Paleiron N, Monnet I; French Lung Cancer Group. Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01). Cancer Manag Res 2019;11:10821-6. [PMID: 31920391 DOI: 10.2147/CMAR.S219984] [Reference Citation Analysis]
327 Levene AP, Singh G, Palmieri C. Therapeutic monoclonal antibodies in oncology. J R Soc Med 2005;98:146-52. [PMID: 15805554 DOI: 10.1258/jrsm.98.4.146] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
328 Li BQ, You J, Huang T, Cai YD. Classification of non-small cell lung cancer based on copy number alterations. PLoS One 2014;9:e88300. [PMID: 24505469 DOI: 10.1371/journal.pone.0088300] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
329 Socinski MA, Waller CF, Idris T, Bondarenko I, Luft A, Beckmann K, Vishweswaramurthy A, Loganathan S, Donnelly C, Hummel MA, Shapiro R, Woods M, Rao A, Nayak VG, Ranganna G, Barve A. Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer. Ther Adv Med Oncol 2021;13:17588359211045845. [PMID: 34819997 DOI: 10.1177/17588359211045845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 McKeage MJ, Jameson MB; AS1404-201 Study Group Investigators. Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. J Thorac Dis 2010;2:199-204. [PMID: 22263047 DOI: 10.3978/j.issn.2072-1439.2010.02.04.1] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
331 Socinski MA. Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. Curr Oncol 2014;21:e691-703. [PMID: 25302040 DOI: 10.3747/co.21.1997] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
332 Ranieri G, Ferrari C, Di Palo A, Marech I, Porcelli M, Falagario G, Ritrovato F, Ramunni L, Fanelli M, Rubini G, Gadaleta CD. Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study. Int J Mol Sci 2017;18:E1458. [PMID: 28684680 DOI: 10.3390/ijms18071458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
333 Suenaga M, Mizunuma N, Kobayashi K, Shinozaki E, Matsusaka S, Chin K, Kuboki Y, Ichimura T, Ozaka M, Ogura M. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. Med Oncol. 2010;27:807-814. [PMID: 19697164 DOI: 10.1007/s12032-009-9289-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
334 Sadowska AM, Nowé V, Janssens A, Boeykens E, De Backer WA, Germonpré PR. Customizing systemic therapy in patients with advanced non-small cell lung cancer. Ther Adv Med Oncol 2011;3:207-18. [PMID: 21904581 DOI: 10.1177/1758834011409000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
335 Carroll NM, Delate T, Menter A, Hornbrook MC, Kushi L, Aiello Bowles EJ, Loggers ET, Ritzwoller DP. Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer. J Oncol Pract 2015;11:356-62. [PMID: 26060223 DOI: 10.1200/JOP.2014.002980] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
336 Geng Q, Shen H, Zhu W, Lu Y, Wang M, Jiang H, Li D. Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study. Onco Targets Ther 2020;13:11529-35. [PMID: 33204107 DOI: 10.2147/OTT.S277532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
337 Bradley D, Rees J. Updates in the management of high-grade glioma. J Neurol 2014;261:651-4. [PMID: 23857040 DOI: 10.1007/s00415-013-7032-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
338 Shin SJ, Hwang JW, Ahn JB, Rha SY, Roh JK, Chung HC. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. Invest New Drugs. 2013;31:1-13. [PMID: 22539090 DOI: 10.1007/s10637-012-9817-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
339 Wozniak AJ, Gadgeel SM. Adjuvant therapy for resected non-small cell lung cancer. Ther Adv Med Oncol 2009;1:109-18. [PMID: 21789116 DOI: 10.1177/1758834009338634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
340 Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther 2012;13:247-63. [PMID: 22481432 DOI: 10.4161/cbt.19594] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
341 An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, Jiang YY. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010;66:813-21. [PMID: 20401474 DOI: 10.1007/s00228-010-0815-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
342 Derman BA, Mileham KF, Bonomi PD, Batus M, Fidler MJ. Treatment of advanced squamous cell carcinoma of the lung: a review. Transl Lung Cancer Res 2015;4:524-32. [PMID: 26629421 DOI: 10.3978/j.issn.2218-6751.2015.06.07] [Cited by in F6Publishing: 36] [Reference Citation Analysis]
343 Bianco R, Damiano V, Tortora G. Combination of biological therapies in non-small cell lung cancer. Ann Oncol 2006;17 Suppl 2:ii52-54. [PMID: 16608984 DOI: 10.1093/annonc/mdj923] [Reference Citation Analysis]
344 Xu P, Li H. [Application of Bevacizumab in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2017;20:272-7. [PMID: 28442017 DOI: 10.3779/j.issn.1009-3419.2017.04.08] [Reference Citation Analysis]
345 Harris JC, Scully MA, Day ES. Cancer Cell Membrane-Coated Nanoparticles for Cancer Management. Cancers (Basel) 2019;11:E1836. [PMID: 31766360 DOI: 10.3390/cancers11121836] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
346 Samanci NS, Celik E. The top 100 cited articles in lung cancer - a bibliometric analysis. Contemp Oncol (Pozn) 2020;24:17-28. [PMID: 32514234 DOI: 10.5114/wo.2020.94725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
347 Gentzler RD, Johnson ML. Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer. Oncologist 2015;20:299-306. [PMID: 25660158 DOI: 10.1634/theoncologist.2014-0212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
348 Yang L, Chen CJ, Guo XL, Wu XC, Lv BJ, Wang HL, Guo Z, Zhao XY. Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis. J Neurooncol 2018;137:49-56. [PMID: 29170906 DOI: 10.1007/s11060-017-2693-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
349 Mehran R, Nilsson M, Khajavi M, Du Z, Cascone T, Wu HK, Cortes A, Xu L, Zurita A, Schier R, Riedel B, El-Zein R, Heymach JV. Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res. 2014;74:2731-2741. [PMID: 24626092 DOI: 10.1158/0008-5472.can-13-2044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
350 Hida K, Maishi N, Torii C, Hida Y. Tumor angiogenesis--characteristics of tumor endothelial cells. Int J Clin Oncol. 2016;21:206-212. [PMID: 26879652 DOI: 10.1007/s10147-016-0957-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 12.3] [Reference Citation Analysis]
351 Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract. 2011;2011:816897. [PMID: 21629798 DOI: 10.4061/2011/816897] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
352 Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder DB, Franklin W, Gazdar A, Hasleton PS, Henderson DW, Kerr KM, Petersen I, Roggli V, Thunnissen E, Tsao M. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 2013;137:668-84. [PMID: 22970842 DOI: 10.5858/arpa.2012-0263-RA] [Cited by in Crossref: 242] [Cited by in F6Publishing: 94] [Article Influence: 24.2] [Reference Citation Analysis]
353 Pall G, Hilbe W. ["Targeted Therapies" in NSCLC - present and future]. Wien Med Wochenschr 2007;157:545-53. [PMID: 18157592 DOI: 10.1007/s10354-007-0482-y] [Reference Citation Analysis]
354 Cheng Y, Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, He J, Shi Y, Chen W, Wang X, Luo Y, Nan K, Jin F, Li B, Zhu J. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. Cancer Med 2020;9:2621-30. [PMID: 32064794 DOI: 10.1002/cam4.2913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
355 Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther 2012;13:247-63. [PMID: 22481432 DOI: 10.4161/cbt.19594] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
356 Levin PA, Dowell JE. Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date. Onco Targets Ther 2017;10:2057-66. [PMID: 28435296 DOI: 10.2147/OTT.S113598] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
357 Tang N, Guo J, Zhang Q, Wang Y, Wang Z. Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget 2016;7:3635-44. [PMID: 26498354 DOI: 10.18632/oncotarget.6184] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
358 Li LJ, Chen DF, Wu GF, Guan WJ, Zhu Z, Liu YQ, Gao GY, Qin YY, Zhong NS. Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma. J Thorac Dis 2018;10:5010-22. [PMID: 30233875 DOI: 10.21037/jtd.2018.07.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
359 Escudier B, Cosaert J, Jethwa S. Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics 2008;2:517-30. [PMID: 19707382 DOI: 10.2147/btt.s3509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
360 Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246. [PMID: 19619339 DOI: 10.1186/1471-2407-9-246] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
361 Zhang D, Zhang X, Zhao C. Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review. Onco Targets Ther 2016;9:3695-704. [PMID: 27382307 DOI: 10.2147/OTT.S103735] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
362 Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. J Thorac Oncol 2013;8:79-88. [PMID: 23232491 DOI: 10.1097/JTO.0b013e318274a85d] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
363 Cheng Y, Zhang T, Xu Q. Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm (2020) 2021;2:692-729. [PMID: 34977873 DOI: 10.1002/mco2.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Ma X, Phi Van V, Kimm MA, Prakash J, Kessler H, Kosanke K, Feuchtinger A, Aichler M, Gupta A, Rummeny EJ, Eisenblätter M, Siveke J, Walch AK, Braren R, Ntziachristos V, Wildgruber M. Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung Cancer. Neoplasia 2017;19:8-16. [PMID: 27940248 DOI: 10.1016/j.neo.2016.11.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
365 Vijayalakshmi R, Krishnamurthy A. Targetable "driver" mutations in non small cell lung cancer. Indian J Surg Oncol 2011;2:178-88. [PMID: 22942608 DOI: 10.1007/s13193-011-0108-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
366 Goudar RK, Vlahovic G. Hypoxia, angiogenesis, and lung cancer. Curr Oncol Rep 2008;10:277-82. [PMID: 18778551 DOI: 10.1007/s11912-008-0043-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
367 Yamamoto K, Ohga N, Hida Y, Maishi N, Kawamoto T, Kitayama K, Akiyama K, Osawa T, Kondoh M, Matsuda K, Onodera Y, Fujie M, Kaga K, Hirano S, Shinohara N, Shindoh M, Hida K. Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br J Cancer. 2012;106:1214-1223. [PMID: 22374465 DOI: 10.1038/bjc.2012.59] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
368 Janowitz T, Williams EH, Marshall A, Ainsworth N, Thomas PB, Sammut SJ, Shepherd S, White J, Mark PB, Lynch AG, Jodrell DI, Tavaré S, Earl H. New Model for Estimating Glomerular Filtration Rate in Patients With Cancer. J Clin Oncol 2017;35:2798-805. [PMID: 28686534 DOI: 10.1200/JCO.2017.72.7578] [Cited by in Crossref: 51] [Cited by in F6Publishing: 10] [Article Influence: 10.2] [Reference Citation Analysis]
369 Bulman W, Saqi A, Powell CA. Acquisition and processing of endobronchial ultrasound-guided transbronchial needle aspiration specimens in the era of targeted lung cancer chemotherapy. Am J Respir Crit Care Med 2012;185:606-11. [PMID: 22071327 DOI: 10.1164/rccm.201107-1199CI] [Cited by in Crossref: 51] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
370 Savci-Heijink CD, Kosari F, Aubry MC, Caron BL, Sun Z, Yang P, Vasmatzis G. The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung. Am J Pathol 2009;174:1629-37. [PMID: 19342368 DOI: 10.2353/ajpath.2009.080778] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
371 Pérol M, Arpin D. [Bevacizumab and non-small cell lung cancer: a new step?]. Rev Mal Respir 2009;26:125-38. [PMID: 19319108 DOI: 10.1016/s0761-8425(09)71590-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
372 Herbst RS. Role of novel targeted therapies in the clinic. Br J Cancer 2005;92 Suppl 1:S21-7. [PMID: 15928655 DOI: 10.1038/sj.bjc.6602605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
373 Chen WL, Kuo KT, Chou TY, Chen CL, Wang CH, Wei YH, Wang LS. The role of cytochrome c oxidase subunit Va in non-small cell lung carcinoma cells: association with migration, invasion and prediction of distant metastasis. BMC Cancer 2012;12:273. [PMID: 22748147 DOI: 10.1186/1471-2407-12-273] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
374 Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, Hayward MC, Cabanski CR, Yin X, Socinski MA, Stinchcombe TE, Thorne LB, Allen TC, Banks PM, Beasley MB, Borczuk AC, Cagle PT, Christensen R, Colby TV, Deblois GG, Elmberger G, Graziano P, Hart CF, Jones KD, Maia DM, Miller CR, Nance KV, Travis WD, Funkhouser WK. Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. Arch Pathol Lab Med 2013;137:32-40. [PMID: 22583114 DOI: 10.5858/arpa.2012-0033-OA] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
375 Villaruz LC, Socinski MA. Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. Eur J Cancer. 2016;56:162-171. [PMID: 26875112 DOI: 10.1016/j.ejca.2015.12.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
376 Wei DC, Yeh YC, Hung JJ, Chou TY, Wu YC, Lu PJ, Cheng HC, Hsu YL, Kuo YL, Chen KY, Lai JM. Overexpression of T-LAK cell-originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma. Cancer Sci 2012;103:731-8. [PMID: 22192142 DOI: 10.1111/j.1349-7006.2011.02197.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
377 VanderMeer R, Chambers S, Van Dam A, Cutz JC, Goffin JR, Ellis PM. Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care? Curr Oncol 2015;22:272-8. [PMID: 26300665 DOI: 10.3747/co.22.2526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
378 Bertino E, Villalona-Calero MA, Ross P, Grever M, Otterson GA. Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer. Ann Thorac Surg 2011;91:640. [PMID: 21256341 DOI: 10.1016/j.athoracsur.2010.07.047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
379 Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol 2018;29:1701-9. [PMID: 29905778 DOI: 10.1093/annonc/mdy196] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
380 Buscarini E, Botella LM, Geisthoff U, Kjeldsen AD, Mager HJ, Pagella F, Suppressa P, Zarrabeitia R, Dupuis-Girod S, Shovlin CL; VASCERN-HHT. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 2019;14:28. [PMID: 30717761 DOI: 10.1186/s13023-018-0982-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 11.3] [Reference Citation Analysis]
381 Zhuang X, Herbert JM, Lodhia P, Bradford J, Turner AM, Newby PM, Thickett D, Naidu U, Blakey D, Barry S. Identification of novel vascular targets in lung cancer. Br J Cancer. 2015;112:485-494. [PMID: 25535734 DOI: 10.1038/bjc.2014.626] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
382 Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist. 2010;15:1179-1191. [PMID: 21045188 DOI: 10.1634/theoncologist.2009-0155] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
383 Eichkorn T, Schunn F, Regnery S, Shafie RE, Hörner-Rieber J, Adeberg S, Herfarth K, Debus J, König L. Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John's wort skin oil. Strahlenther Onkol 2021;197:644-9. [PMID: 33491130 DOI: 10.1007/s00066-020-01739-0] [Reference Citation Analysis]
384 Reynolds AR. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response 2010;8:253-84. [PMID: 20877487 DOI: 10.2203/dose-response.09-049.Reynolds] [Cited by in Crossref: 64] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
385 Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla C, Wistuba II, Behrens C, Timsit JF, Pio R, Field JK, Montuenga LM. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol 2012;30:1129-36. [PMID: 22355056 DOI: 10.1200/JCO.2011.37.4231] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
386 Stinchcombe TE. Novel agents in development for advanced non-small cell lung cancer. Ther Adv Med Oncol 2014;6:240-53. [PMID: 25342991 DOI: 10.1177/1758834014532510] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
387 Savic S, Bihl MP, Bubendorf L. [Non-small cell lung cancer. Subtyping and predictive molecular marker investigations in cytology]. Pathologe 2012;33:301-7. [PMID: 22711372 DOI: 10.1007/s00292-012-1577-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
388 Korpanty G, Smyth E, Carney DN. Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? J Thorac Dis 2011;3:19-29. [PMID: 22263059 DOI: 10.3978/j.issn.2072-1439.2010.11.11] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
389 Gazdar AF. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 2010;29:37-48. [PMID: 20127143 DOI: 10.1007/s10555-010-9201-z] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
390 Li Y, Yi Y, Lin A, Luo P, Zhang J. A comparison of the efficacy of antiangiogenic agents combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis. Cancer Cell Int 2020;20:548. [PMID: 33292249 DOI: 10.1186/s12935-020-01639-4] [Reference Citation Analysis]
391 Ranganathan A, Lee D, Langer C, Yoneda K, Gandara DR. 2006 Highlights From: 7th International Lung Cancer Congress Workshop Maui, HI; June 28-July 1, 2006. Clinical Lung Cancer 2006;8:88-92. [DOI: 10.1016/s1525-7304(11)70487-9] [Reference Citation Analysis]
392 Liu J, Fan L, Wang H, Sun G. Autophagy, a double-edged sword in anti-angiogenesis therapy. Med Oncol 2016;33:10. [PMID: 26715036 DOI: 10.1007/s12032-015-0721-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
393 Xu Y, Ding VW, Zhang H, Zhang X, Jablons D, He B. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Ther Clin Risk Manag 2016;12:807-16. [PMID: 27307741 DOI: 10.2147/TCRM.S92996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
394 Lee SM, Hackshaw A. A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial. Cancer Med 2013;2:360-6. [PMID: 23930213 DOI: 10.1002/cam4.74] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
395 Isakov L, Jin B, Jacobs IA. Statistical Primer on Biosimilar Clinical Development. Am J Ther 2016;23:e1903-10. [PMID: 26766293 DOI: 10.1097/MJT.0000000000000391] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
396 Hirsh V. Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol 2010;17:13-23. [PMID: 20404973 DOI: 10.3747/co.v17i2.549] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
397 Hilbe W, Manegold C, Pircher A. Targeting angiogenesis in lung cancer - Pitfalls in drug development. Transl Lung Cancer Res 2012;1:122-8. [PMID: 25806168 DOI: 10.3978/j.issn.2218-6751.2012.01.01] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
398 Nishimura T, Furihata M, Kubo H, Tani M, Agawa S, Setoyama R, Toyoda T. Intracranial hemorrhage in patients treated with bevacizumab: Report of two cases. World J Gastroenterol 2011; 17(39): 4440-4444 [PMID: 22110272 DOI: 10.3748/wjg.v17.i39.4440] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
399 Sedlaczek O, Grüllich C, Röthke M, Schlemmer HP, Kauczor HU. [Organ toxicity of medicinal tumor therapy: morphological correlates]. Radiologe 2013;53:329-35. [PMID: 23536030 DOI: 10.1007/s00117-012-2428-7] [Reference Citation Analysis]
400 Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 2009;15:5040-8. [PMID: 19671872 DOI: 10.1158/1078-0432.CCR-09-0520] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
401 Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S. Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. J Clin Med 2020;9:E1268. [PMID: 32349387 DOI: 10.3390/jcm9051268] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
402 Nana-Sinkam SP, Powell CA. Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e30S-9S. [PMID: 23649444 DOI: 10.1378/chest.12-2346] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
403 Zhou S, Zuo L, He X, Pi J, Jin J, Shi Y. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy. Thorac Cancer 2018;9:1354-60. [PMID: 30152052 DOI: 10.1111/1759-7714.12827] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
404 Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget 2014;5:11154-67. [PMID: 25525888 DOI: 10.18632/oncotarget.2568] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
405 Wilkerson MD, Schallheim JM, Hayes DN, Roberts PJ, Bastien RR, Mullins M, Yin X, Miller CR, Thorne LB, Geiersbach KB, Muldrew KL, Funkhouser WK, Fan C, Hayward MC, Bayer S, Perou CM, Bernard PS. Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens. J Mol Diagn 2013;15:485-97. [PMID: 23701907 DOI: 10.1016/j.jmoldx.2013.03.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
406 Pirker R, Filipits M. Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. Cancer Metastasis Rev 2016;35:141-50. [PMID: 26970967 DOI: 10.1007/s10555-016-9612-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
407 Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H, Ueno M, Wada H, Fukushima M. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006;95:607-15. [PMID: 16880781 DOI: 10.1038/sj.bjc.6603297] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
408 Huang LT, Cao R, Wang YR, Sun L, Zhang XY, Guo YJ, Zhao JZ, Zhang SL, Jing W, Song J, Han CB, Ma J. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials. BMC Cancer 2021;21:426. [PMID: 33865364 DOI: 10.1186/s12885-021-08136-5] [Reference Citation Analysis]
409 Ong LC, Song IC, Jin Y, Kee IH, Siew E, Yu S, Thng CH, Huynh H, Chow PK. Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model. Mol Imaging Biol 2009;11:334-42. [PMID: 19330383 DOI: 10.1007/s11307-009-0213-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
410 Foster CH, Dave P, Sherman JH. Chemotherapy for the Management of Cerebral Metastases. Neurosurg Clin N Am 2020;31:603-11. [PMID: 32921355 DOI: 10.1016/j.nec.2020.06.009] [Reference Citation Analysis]
411 Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Checcacci D, Saggese M, Di Costanzo F. Bevacizumab in non-small cell lung cancer. Drugs 2008;68:737-46. [PMID: 18416583 DOI: 10.2165/00003495-200868060-00002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
412 Rajpar S, Osio A, Besse B. [Management of targeted molecular therapies toxicities in thoracic cancerology]. Rev Pneumol Clin 2008;64:104-10. [PMID: 18589292 DOI: 10.1016/j.pneumo.2008.04.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
413 Davidson MR, Gazdar AF, Clarke BE. The pivotal role of pathology in the management of lung cancer. J Thorac Dis 2013;5 Suppl 5:S463-78. [PMID: 24163740 DOI: 10.3978/j.issn.2072-1439.2013.08.43] [Cited by in F6Publishing: 58] [Reference Citation Analysis]
414 Martin M, Wei H, Lu T. Targeting microenvironment in cancer therapeutics. Oncotarget 2016;7:52575-83. [PMID: 27270649 DOI: 10.18632/oncotarget.9824] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
415 Rezkallah KNM, Ahmed A, Patel S, Kozma K. A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome. BMJ Case Rep 2019;12:bcr-2018-227785. [PMID: 30739089 DOI: 10.1136/bcr-2018-227785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
416 Wakelee H, Kelly K, Edelman MJ. 50 Years of progress in the systemic therapy of non-small cell lung cancer. Am Soc Clin Oncol Educ Book 2014;:177-89. [PMID: 24857075 DOI: 10.14694/EdBook_AM.2014.34.177] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
417 Bruce JY, LoRusso PM, Goncalves PH, Heath EI, Sadowski E, Shalinsky DR, Zhang Y, Traynor AM, Breazna A, Ricart AD, Tortorici M, Liu G. A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors. Cancer Chemother Pharmacol 2016;77:527-38. [PMID: 26791870 DOI: 10.1007/s00280-016-2958-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
418 Yan W, Wistuba II, Emmert-Buck MR, Erickson HS. Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. Am J Cancer Res 2011;1:275-300. [PMID: 21938273 DOI: 10.1158/1538-7445.am2011-275] [Cited by in Crossref: 10] [Cited by in F6Publishing: 54] [Article Influence: 1.3] [Reference Citation Analysis]
419 Cheon YH, Kim MJ, Kang MG, Kim HJ, Lee SS, Kim CY, Jeon DH, Kim YE, Lee GW. Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer. Yonsei Med J 2011;52:695-8. [PMID: 21623617 DOI: 10.3349/ymj.2011.52.4.695] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
420 Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol. 2008;10:624-630. [PMID: 18539884 DOI: 10.1215/15228517-2008-010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
421 Horn L, Sandler AB. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clin Lung Cancer 2009;10 Suppl 1:S7-16. [PMID: 19362948 DOI: 10.3816/CLC.2009.s.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
422 Hurtado-de-Mendoza D, Loaiza-Bonilla A, Bonilla-Reyes PA, Tinoco G, Alcorta R. Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives. Cureus 2017;9:e1258. [PMID: 28649481 DOI: 10.7759/cureus.1258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
423 Zhang S, Xu P, Yuan C, Ou W. [Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin 
in Patients with IIIa Lung Adenocarcinoma]. Zhongguo Fei Ai Za Zhi 2015;18:365-8. [PMID: 26104893 DOI: 10.3779/j.issn.1009-3419.2015.06.06] [Reference Citation Analysis]
424 Selvaraj D, Gangadharan V, Michalski CW, Kurejova M, Stösser S, Srivastava K, Schweizerhof M, Waltenberger J, Ferrara N, Heppenstall P, Shibuya M, Augustin HG, Kuner R. A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain. Cancer Cell 2015;27:780-96. [PMID: 26058077 DOI: 10.1016/j.ccell.2015.04.017] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
425 Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e341S-e368S. [PMID: 23649446 DOI: 10.1378/chest.12-2361] [Cited by in Crossref: 121] [Cited by in F6Publishing: 116] [Article Influence: 13.4] [Reference Citation Analysis]
426 Pal SK, Figlin RA, Reckamp K. Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther 2010;9:1931-44. [PMID: 20571071 DOI: 10.1158/1535-7163.MCT-10-0239] [Cited by in Crossref: 55] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
427 Reck M, Barlesi F, Crinò L, Henschke CI, Isla D, Stiebeler S, Spigel DR. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 2012;23:1111-20. [PMID: 22056855 DOI: 10.1093/annonc/mdr463] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 5.7] [Reference Citation Analysis]
428 Ai B, Yang Y. [Progress of Bevacizumab in the Front-line Treatment of Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:626-30. [PMID: 32702797 DOI: 10.3779/j.issn.1009-3419.2020.101.34] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
429 Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-6. [PMID: 18235126 DOI: 10.1200/JCO.2007.13.9303] [Cited by in Crossref: 257] [Cited by in F6Publishing: 99] [Article Influence: 18.4] [Reference Citation Analysis]
430 Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest 2007;117:2740-50. [PMID: 17909619 DOI: 10.1172/JCI31809] [Cited by in Crossref: 144] [Cited by in F6Publishing: 88] [Article Influence: 9.6] [Reference Citation Analysis]
431 Tane S, Nishio W, Ogawa H, Hokka D, Tane K, Tanaka Y, Tauchi S, Uchino K, Sakai Y, Ohbayashi C, Yoshimura M, Maniwa Y. Clinical significance of the 'not otherwise specified' subtype in candidates for resectable non-small cell lung cancer. Oncol Lett 2014;8:1017-24. [PMID: 25120650 DOI: 10.3892/ol.2014.2302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
432 Kim ES, Balser S, Rohr KB, Lohmann R, Liedert B, Schliephake D. Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC. JTO Clin Res Rep 2022;3:100248. [PMID: 34993498 DOI: 10.1016/j.jtocrr.2021.100248] [Reference Citation Analysis]
433 Berge EM, Doebele RC. Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. Drugs 2013;73:517-32. [PMID: 23591906 DOI: 10.1007/s40265-013-0032-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
434 Gold KA, Wistuba II, Kim ES. New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res 2012;18:3002-7. [PMID: 22461458 DOI: 10.1158/1078-0432.CCR-11-2055] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
435 Kai Y, Amatya VJ, Kushitani K, Kambara T, Suzuki R, Fujii Y, Tsutani Y, Miyata Y, Okada M, Takeshima Y. Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung. Transl Lung Cancer Res 2021;10:766-75. [PMID: 33718020 DOI: 10.21037/tlcr-20-857] [Reference Citation Analysis]
436 Kellar A, Egan C, Morris D. Preclinical Murine Models for Lung Cancer: Clinical Trial Applications. Biomed Res Int 2015;2015:621324. [PMID: 26064932 DOI: 10.1155/2015/621324] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 10.3] [Reference Citation Analysis]
437 Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep 2005;7:419-34. [PMID: 16221379 DOI: 10.1007/s11912-005-0007-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
438 Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmgenomics Pers Med 2010;3:79-85. [PMID: 23226044 DOI: 10.2147/pgpm.s7940] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
439 Duan FG, Wang MF, Cao YB, Dan Li, Li RZ, Fan XX, Khan I, Lai HL, Zhang YZ, Hsiao WW, Yao XJ, Wu QB, Liu L, Tang YJ, Leung EL. MicroRNA-421 confers paclitaxel resistance by binding to the KEAP1 3'UTR and predicts poor survival in non-small cell lung cancer. Cell Death Dis 2019;10:821. [PMID: 31659154 DOI: 10.1038/s41419-019-2031-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
440 Larkins E, Scepura B, Blumenthal GM, Bloomquist E, Tang S, Biable M, Kluetz P, Keegan P, Pazdur R. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy. Oncologist 2015;20:1320-5. [PMID: 26446239 DOI: 10.1634/theoncologist.2015-0221] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
441 Lordick F, Siewert JR. [Bevacizumab (Avastin) related surgical complications: comment to Abbrederis K et al. (2007)]. Chirurg 2008;79:356-60. [PMID: 17453166 DOI: 10.1007/s00104-007-1340-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
442 Gupta N, Sekar A, Rajwanshi A. Role of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present era. J Cytol 2015;32:217-22. [PMID: 26811567 DOI: 10.4103/0970-9371.171219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
443 Metodieva S. Angiogenesis and Non Small Cell Lung Cancer. Balkan Journal of Medical Genetics 2008;11. [DOI: 10.2478/v10034-008-0011-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
444 Cooper MR, Binkowski C, Hartung J, Towle J. Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer. Onco Targets Ther 2016;9:1953-60. [PMID: 27110124 DOI: 10.2147/OTT.S80239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
445 Kawachi H, Tamiya M, Matsumoto K, Tamiya A, Yanase T, Tanizaki S, Kumagai T. Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study. Invest New Drugs 2022. [PMID: 35024985 DOI: 10.1007/s10637-022-01214-w] [Reference Citation Analysis]
446 Hanna RM, Lopez E, Wilson J, Barathan S, Cohen AH. Minimal change disease onset observed after bevacizumab administration. Clin Kidney J. 2016;9:239-244. [PMID: 26985375 DOI: 10.1093/ckj/sfv139] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
447 Yan DF, Yan SX, Yang JS, Wang YX, Sun XL, Liao XB, Liu JQ. Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature. BMC Cancer 2010;10:49. [PMID: 20170543 DOI: 10.1186/1471-2407-10-49] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
448 Handorf EA, McElligott S, Vachani A, Langer CJ, Bristol Demeter M, Armstrong K, Asch DA. Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J Oncol Pract 2012;8:267-74. [PMID: 23277762 DOI: 10.1200/JOP.2011.000502] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
449 Jovčevska I, Kočevar N, Komel R. Glioma and glioblastoma - how much do we (not) know? Mol Clin Oncol 2013;1:935-41. [PMID: 24649273 DOI: 10.3892/mco.2013.172] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 10.3] [Reference Citation Analysis]
450 Brandao GD, Brega EF, Spatz A. The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. Curr Oncol 2012;19:S24-32. [PMID: 22787408 DOI: 10.3747/co.19.1058] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
451 Wang J, Chen J, Guo Y, Wang B, Chu H. Strategies targeting angiogenesis in advanced non-small cell lung cancer. Oncotarget 2017;8:53854-72. [PMID: 28881856 DOI: 10.18632/oncotarget.17957] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]
452 Langevin SM, Kratzke RA, Kelsey KT. Epigenetics of lung cancer. Transl Res 2015;165:74-90. [PMID: 24686037 DOI: 10.1016/j.trsl.2014.03.001] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 9.6] [Reference Citation Analysis]
453 Hirai F, Seto T, Inamasu E, Shimokawa M, Toyokawa G, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y. Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. Oncol Lett 2015;9:2577-82. [PMID: 26137109 DOI: 10.3892/ol.2015.3086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
454 Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci 2013;14:9338-64. [PMID: 23629668 DOI: 10.3390/ijms14059338] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
455 Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 2015;10:e0136324. [PMID: 26331473 DOI: 10.1371/journal.pone.0136324] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
456 Chang Q, Zhang Y, Xu J, Zhong R, Qiang H, Zhang B, Han B, Qian J, Chu T. First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China. Thorac Cancer 2019;10:1043-50. [PMID: 30900826 DOI: 10.1111/1759-7714.13025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
457 Wu W, Tang J, Wu Y, Zhu Y, Xu L, Shi H, Meng Q, Liu Z, Guo L, Tao H, Li M, Liu Z. [Long-term survival of a patient with advanced non-small cell lung cancer on bevacizumab therapy: case report and review of the literature]. Zhongguo Fei Ai Za Zhi 2013;16:325-9. [PMID: 23769349 DOI: 10.3779/j.issn.1009-3419.2013.06.10] [Reference Citation Analysis]
458 Casillas AL, Toth RK, Sainz AG, Singh N, Desai AA, Kraft AS, Warfel NA. Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res 2018;24:169-80. [PMID: 29084916 DOI: 10.1158/1078-0432.CCR-17-1318] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
459 Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011;377:1846-54. [PMID: 21621716 DOI: 10.1016/S0140-6736(11)60545-X] [Cited by in Crossref: 266] [Cited by in F6Publishing: 144] [Article Influence: 24.2] [Reference Citation Analysis]
460 Zielinski C, Knapp S, Mascaux C, Hirsch F. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013;24:1170-9. [PMID: 23393121 DOI: 10.1093/annonc/mds647] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 6.6] [Reference Citation Analysis]
461 Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jürgensmeier JM, Milas L, Ang K, Herbst RS, O'Reilly MS. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;69:1534-43. [PMID: 17889445 DOI: 10.1016/j.ijrobp.2007.07.2350] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
462 Zhao X, Huffman KE, Fujimoto J, Canales JR, Girard L, Nie G, Heymach JV, Wistuba II, Minna JD, Yu Y. Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer. J Am Soc Mass Spectrom 2017;28:2078-89. [PMID: 28752479 DOI: 10.1007/s13361-017-1706-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
463 Ernani V, Ganti AK. Immunotherapy in treatment naïve advanced non-small cell lung cancer. J Thorac Dis 2018;10:S412-21. [PMID: 29593887 DOI: 10.21037/jtd.2017.12.94] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
464 Dubey S, Powell CA. Update in lung cancer 2007. Am J Respir Crit Care Med 2008;177:941-6. [PMID: 18434333 DOI: 10.1164/rccm.200801-107UP] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
465 Nishimura T, Kato H, Ikeda N, Kihara M, Nomura M, Kato Y, Marko-Varga G. Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care. Int J Proteomics 2012;2012:921901. [PMID: 22685658 DOI: 10.1155/2012/921901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
466 Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 2018;11:5059-74. [PMID: 30174444 DOI: 10.2147/OTT.S166151] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
467 Mishima H, Oba K, Sakamoto J, Muro K, Yoshino T, Hyodo I, Maehara Y. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study). Jpn J Clin Oncol. 2012;42:134-138. [PMID: 22167662 DOI: 10.1093/jjco/hyr180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
468 Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol. 2016;13:209-227. [PMID: 26718105 DOI: 10.1038/nrclinonc.2015.213] [Cited by in Crossref: 109] [Cited by in F6Publishing: 93] [Article Influence: 15.6] [Reference Citation Analysis]
469 Lee Y, Jung HA, Lee M, Choi JW, Kong D, Seol HJ, Nam D, Lee J, Lee S. Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma. J Neurooncol. [DOI: 10.1007/s11060-021-03930-4] [Reference Citation Analysis]
470 Sahni V, Guvenc-Tuncturk S, Paintal HS, Kuschner WG. Bronchogenic squamous cell carcinoma mass with central photopenia on FDG-PET scan. Clin Med Res 2012;10:36-7. [PMID: 21817117 DOI: 10.3121/cmr.2011.1013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
471 Kutluk Cenik B, Ostapoff KT, Gerber DE, Brekken RA. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther 2013;12:992-1001. [PMID: 23729403 DOI: 10.1158/1535-7163.MCT-12-0995] [Cited by in Crossref: 64] [Cited by in F6Publishing: 39] [Article Influence: 7.1] [Reference Citation Analysis]
472 Liang W, Wu X, Hong S, Zhang Y, Kang S, Fang W, Qin T, Huang Y, Zhao H, Zhang L. Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses. PLoS One 2014;9:e109757. [PMID: 25329056 DOI: 10.1371/journal.pone.0109757] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
473 Jackson AL, Zhou B, Kim WY. HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets 2010;14:1047-57. [PMID: 20854179 DOI: 10.1517/14728222.2010.511617] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
474 Jacobsen B, Kriegbaum MC, Santoni-Rugiu E, Ploug M. C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. World J Clin Oncol 2014; 5(4): 621-632 [PMID: 25302166 DOI: 10.5306/wjco.v5.i4.621] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
475 Furuto Y, Hashimoto H, Namikawa A, Outi H, Takahashi H, Horiuti H, Honda K, Shibuya Y. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report. BMC Nephrol 2018;19:273. [PMID: 30340546 DOI: 10.1186/s12882-018-1074-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
476 Shiba H, Takeuchi K, Hiramatsu R, Furuse M, Nonoguchi N, Kawabata S, Kuroiwa T, Kondo N, Sakurai Y, Suzuki M, Ono K, Oue S, Ishikawa E, Michiue H, Miyatake SI. Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas - A Pilot Study. Neurol Med Chir (Tokyo) 2018;58:487-94. [PMID: 30464150 DOI: 10.2176/nmc.oa.2018-0111] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
477 Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol. 2009;27:1405-1412. [PMID: 19224857 DOI: 10.1200/jco.2008.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
478 Abramson RG, Burton KR, Yu JP, Scalzetti EM, Yankeelov TE, Rosenkrantz AB, Mendiratta-Lala M, Bartholmai BJ, Ganeshan D, Lenchik L, Subramaniam RM. Methods and challenges in quantitative imaging biomarker development. Acad Radiol 2015;22:25-32. [PMID: 25481515 DOI: 10.1016/j.acra.2014.09.001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 8.0] [Reference Citation Analysis]